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Ter vermindering van kinetische resistentie verdient het de voorkeur de cyto-
statische behandeling van AML patiënten te combineren met individueel 
geselecteerde groeifactoren, 
-dit proefschrift-
Aangezien leukemische stamcellen langzaam proliferende cellen zijn,ver-
dient het de voorkeur AML patiënten langduriger dan nu gebruikelijk is te 
behandelen met chemotherapie in combinatie met groeifactoren, 
-dit proefschrift-
Door middel van IdUrd labeling kan het percentage donogene cellen in 
S-fase nauwkeuriger worden bepaald dan met de gebruikelijke thymidine 
suicide techniek, 
-dit proefschrift-
De mobiliteit van cellen in semi-solide kweekbodems kan het moeilijk maken 
een uitspraak te doen over de clonale origine van deze cellen. "Single-cell" 
assays zijn een oplossing voor dit probleem. 
AML patiënten in eerste complete remissie verkrijgen door behandeling met 
allogene of autologe beenmergtransplantatie een betere ziektevrije overle-
ving dan met intensieve chemotherapie. 
-Zittoun et al. .NEnglJMed 1995,332:217-
Een goede arts verstaat de kunst om samen met een patient en/of diens fami-
lie de grens van een menswaardig leven te bepalen. 
Een goede ontslagbrief herkent men aan één A4-tje. 
Wat baat er kaars of bril, als de uil niet zien wil. 
-Spreekwoord ten tijde van Jan Steen-
De agressiviteit van mede-automobilisten is omgekeerd evenredig aan de 
grootte van de auto die men zelf bestuurt. 
De producenten van lange broeken spelen onvoldoende in op de toegenomen 
beenlengte van Nederlandse vrouwen. 
Het uitrijden van de Elfstedentocht zal met het oplopen van het Startnummer 
in toenemende mate afhangen van het kluunvermogen van de deelnemende 
schaats (t) er. 
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Abbreviations 
AML 
ARA-C 
ARA-CDP 
ARA-CMP 
ARA-CTP 
ARA-U 
BFU-E 
BM 
BrdU 
ce 
CdR-kinase 
CFU-GM 
CFU-L 
CI 
CML 
C-MPL 
CR 
CSF 
DAB 
dCTP 
DMSO 
DNA 
EPO 
FAB 
FCS 
FCM 
FITC 
FL 
G-CSF 
G-PBS 
- acute myeloid leukemia = acute 
cytic leukemia 
- cytosine arabinoside 
- Ara-C diphosphate 
- Ara-C monophosphate 
- Ara-C triphosphate 
- uracil aiabinoside 
- burst forming umt-erythroid 
- bone marrow 
- bromodeoxyuridine 
- counterflow centri fugati on 
- deoxycytidine kinase 
- colony forming unit-granulocyt 
- leukemic colony forming unit 
- confidence interval 
- chronic myeloid leukemia 
- thrombopoietin 
- complete remission 
- colony-stimulating factor 
nonlympho-
:e/monocyte 
- 3,3-diaminobenzidin tetrahydrochlonde 
- deoxycytidine 5 'triphosphate 
- dimethylsulfoxide 
- deoxyribonucleic acid 
- erythropoietin 
- French-American-British Coope 
- fetal calf serum 
- flow cytometry 
- fluorescein isolhiocyanate 
- FLK-2/FLT-3 hgand 
granulocyte colony-stimulating 
- glucose-phosphate-buffered sah 
rative Group 
factor 
ne 
G6PD 
GM-CSF 
HBSS 
HGF 
HPCM 
HPLC 
HRP 
HSA 
HSC 
HU 
3H-TdR 
ID50 
IdUrd 
IL 
IMDM 
ISH 
lUra 
LTBMC 
M-CSF 
MDS 
MoAb 
NC 
PB 
PBS 
PHS 
PI 
RFLP 
SCF 
SD 
SEM 
- glucose-6-phosphate dehydrogenase 
- granulocyte-macrophage 
colony-stimulating factor 
- Hanks' balanced salt solution 
- hematopoietic growth factor 
- human placenta-conditioned medium 
- high-performance liquid chromatography 
- horseradish peroxidase 
- human serum albumin 
- hematopoietic stem cell 
- hydroxyurea 
- tntiated thymidine 
- 5 0% inhibition dose 
- ìododeoxyundine 
- interleukin 
- Iscove's modified Dulbecco's medium 
- in situ hybridization 
- 5-iodouracil 
- long-term bone marrow culture 
- macrophage colony-stimulating factor 
- myelodysplastic syndrome 
- monoclonal antibody 
- nucleated cells 
- peripheral blood 
- phosphate-buffered saline 
- pooled human serum 
- propidium iodide 
- restriction fragment length polymorphisms 
- stem cell factor 
- standard deviation 
- standard error of the mean 
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Chapter 1 
Introduction and plan of investigation 
Introduction 
Normal and Leukemic Hematopoiesis 
The production of normal blood cells takes mainly place in the bone marrow. 
A relatively small number of pluripotent stem cells is responsible for the pro-
duction of large quantaties of mature blood cells. Stem cells can differentiate 
to committed progenitor cells which can proliferate and differentiate to neu-
trophils, lymphocytes, monocytes, basophils, eosinophils, macrophages, 
erythrocytes and platelets. In addition, they also can produce new stem cells 
(self-renewal). Normal hematopoiesis is tightly controlled by hematopoietic 
growth factors (HGFs) (Fig. 1). Both stimulators and inhibitors of hemato-
poiesis have been identified. ' 8 
Acute myeloid leukemia (AML) is considered to be the result of a clo-
nal expansion of one single transformed cell.9· ' ° Chromosomal abnormalities 
can be detected in the majority of the AMLs. ' ' The origin of the leukemic clo-
ne may be either a pluripotent stem cell or a cell restricted to the granulocyte-
monocyte pathway9 ·10 ·12 ·13 Hematopoiesis in AML is characterized by an 
accumulation of immature blasts that fail to differentiate to functional granu-
locytes or monocytes. Normal hematopoiesis is suppressed by displacement 
of the normal hematopoietic stem cells by leukemic cells, by production of 
inhibitory factors, by direct cellular inhibition, or by a combination of these 
processes.10·13 
Myelodysplasie syndrome (MDS) is characterized by dyshemato-
poiesis. One to three cell lines may be involved. As a result, patients will suffer 
from anemia, granulocytopenia and/or thrombocytopenia.14 In time, the 
disease may progress to overt acute leukemia. The abnormal preleukemic 
clone is assumed to arise at stem cell level.15 Like in AML, chromosomal 
abnormalities are not uncommon in MDS (25-50%).16 Observations suggest 
that (pre)leukemic clones may be organized in a fashion similar to normal 
hematopoiesis, with leukemic stem cells generating large numbers of 
somewhat more mature leukemic 'end' cells with a limited proliferation 
capacity. '3· '7 · ' 8 The proliferation and survival of leukemic progenitor cells is 
regulated by the same HGFs that control normal hematopoiesis. ' 8 
1 0 I C H A P T E R O N E 
Based on morphology and cytochemistry, AML and MDS can be distin-
guished into subtypes. Table 1 and 2 show the classifications according to the 
French-American-British (FAB) nomenclature.19·20 
^ basophil 
eosinophil 
neutrophil 
monocyte/ 
macrophage 
platelets 
erythrocytes 
Figure 1 simplified scheme of normal hematopoiesis. For explanation of the abbreviations see list. 
Table 1 Morphological classification of AML 
according to FAB 
Table 2 Morphological classification of MDS 
according to FAB 
AML-MO acute myeloid leukemia without differentiation 
AML-M1 acute myeloid leukemia with minimal 
differentiation 
AML-M2 acute myeloid leukemia with differentiation 
AML-M3 acute promyelocytic leukemia 
AML-M4 acute myelomonocytic leukemia 
AML-M5 acute monocytic leukemia 
AML-M6 acute erythrocytic leukemia 
AML-M7 acute megakaryocytic leukemia 
MDS-RA refractory anemia 
MDS-RARS refractory anemia with ring sideroblasts 
MDS-RAEB refractory anemia with excess of blasts 
MDS-CMML chronic myelomonocytic leukemia 
MDS-RAEB-f refractory anemia with excess of blasts in 
transformation 
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In V i t ro G r o w t h of Progeni tor Cells 
Growth factors formal and leukemic progenitors can be cultured in vitro. 
Before the identification and production of HGFs, conditioned media and 
feeder layers were used to stimulate cultures.1 7 In the past years, studies 
showed that interleukin-3 (IL-3), granulocyte-macrophage colony-stimula­
ting factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) not 
only support the growth of normal clonogenic cells, but also stimulate leuke­
mic colony-forming cells in the majority of AML patients.2 ' ~23 More recently, 
stem cell factor (SCF) has been identified as a regulatory molecule in both 
normal and leukemic hematopoiesis. 2 4 - 2 6 Other cytokines like macrophage 
colony-stimulating factor (M-CSF), interleukin-5 (IL-5), interleukin-6 (IL-
6), and interleukin-11 (IL-11 ) exert less pronounced effects on myeloid leu­
kemic c e l l s . 2 2 , 2 7 2 9 
Growth characteristics
 lnn№) c u i t u r e d progenitor cells of normal bone mar­
row produce large colonies consisting of 50 to > 10,000 differentiated cells. 
In contrast, AML progenitors exhibit aberrant growth patterns predominantly 
consisting of small clusters (maximum cluster size, 20 cells) or large clusters 
(maximum cluster size, 40 cells). Less frequently, leukemic colonies of >50 
cells are cultured or AML clonogenic cells appear to be nongrowing in vitro.30 
Some leukemias can be cultured in vitro without the addition of exogenous 
growth factors. These spontaneously growing AMLs may produce their own 
growth factors (autocrine growth) 3 ' or may respond to low levels of growth 
factors produced by accessory cells such as monocytes of T-lymphocytes. 
AML aggregates consist mainly of morphologically immature cells. 
Since this is not always the case, additional techniques like karyotyping, sur­
face marker studies, and glucose-6-phosphate dehydrogenase (G6PD) analy­
sis have been developed to establish the leukemic origin of cultured progeni­
tor cells. 9 · 1 0 · 3 2 · 3 3 
The Cell Cycle 
Proliferating cells need to traverse through the cell cycle. Several phases can be 
distinguished (Fig. 2). The interval between the mitotic phase (M-phase, du­
ring which cell division takes place) and the S-phase is called G \ -phase. Du­
ring S-phase, DNA synthesis results in a doubling of the cellular DNA content. 
The period between S-phase and mitosis is defined as the G2-phase. Cells can 
be reversibly out of cycle (resting phase or Go-phase). Terminally differentia­
ted cells are irreversibly out of cycle. Both differentiation and programmed 
cell death (apoptosis) can lead to cell death. Apoptosis is characterized by 
DNA degradation into fragments and subsequent cell désintégration.34 
1 2 I С Н Д Р Т Е І O N E 
• gure 2 The conceptofthe cell cycle. 
Methods to Measure S-phase Cells 
Several suicide techniques are available to determine in vitro the percentage of 
clonogenic cells in S-phase.3S~37 After short-term exposure to tritiated thy-
midine (3H-TdR), hydroxyurea (HU), or cytosine arabinoside (Ara-C), the 
fractional reduction in cloning efficiency is considered to reflect the propor-
tion of colony-forming cells in S-phase. The estimation of progenitors in S-
phase by suicide techniques may not always be accurate.36,37 Non-S-phase 
cells, probably late Gi cells, can take up 3H-TdR and eventually will be 
killed.36 This may result in an overestimation of the percentage of cells in S-
phase. In addition, the confidence intervals of colony-forming assays are sub-
stantial. Statistically, this has a great impact on the accuracy of the suicide 
index, since calculation of the suicide index is based on the subtraction and 
division of colony numbers. 
More recently, iododeoxyuridine (IdUrd) has become available for 
kinetic studies. This nonradioactive thymidine analog is incorporated into 
DNA during S-phase and can be detected by anti-IdUrd antibodies.38·39 IdUrd 
can be used for both in vitro and in vivo studies. 
1-ß-D arab ino furanosy lcy tos ine (Ara-C) 
Ara-C is a deoxycytidine analog with substantial cytotoxic activity against 
AML.40 In vivo, Ara-C is rapidly deaminated by deoxycytidine deaminase to the 
inactive metabolite uracil arabinoside (Ara-U).41 Ara-C is intracellularly 
phosphorylated to its monophosphate (Ara-CMP) by deoxycytidine kinase 
(CdR-kinase). The natural substrate for this enzyme, deoxycytidine, has a 
higher affinity for CdR-kinase than Ara-C. Phosphorylation of Ara-C to Ara-
CMP is therefore influenced by the intracellular pools of deoxycytidine. 
Subsequent activation of Ara-CMP to Ara-CDP and Ara-CTP is facilitated by 
deoxycytidylate kinase and nucleoside diphosphokinase respectively. The 
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active metabolite Ага-СТР competes with deoxycytidine 5' triphosphate 
(dCTP) for binding to DNA polymerase and subsequent incorporation into 
cellular DNA.42 The chain terminating activity of incorporated Ara-CTP 
results in inhibition of DNA synthesis. Hence, Ara-C is predominantly cyto­
toxic to S-phase cells. Consequently, cells not in S-phase may escape toxicity. 
This mechanism is called kinetic resistance 
In Situ Hybridization (ISH) 
As stated earlier, the majority of the AMLs and up to 50% of the MDSs have 
chromosomal abnormalities."· 1 6 Chromosomal aberrations can be detected 
by chromosome banding techniques (karyotyping) .Unfortunately only meta-
phases can be analyzed with karyotyping. A low number of mitotic cells and 
selection of fast growing subpopulations may hamper this technique.4 3 ISH 
overcomes these limitations. With nonradioactive chromosome-specific 
DNA probes, numerical and structural chromosome aberrations can be detec­
ted in both metaphase spreads and interphase nuclei.4 4 
Plan of Investigation 
Although 60 to 70% of newly diagnosed AML patients achieve complete 
remission (CR) with chemotherapy, the majority eventually relapses and 
becomes more and more resistant to chemotherapy.4 5 Non- or slowly cy­
cling cells may escape chemotherapy through kinetic resistance. Metabolic 
resistance, for instance through P-glycoprotein expression is another mecha­
nism of resistance to therapy.4 6 Leukemic stem cells are held responsible for 
the maintenance of the leukemia. Hence, the aim of cytotoxic therapy is era­
dication of these leukemic stem cells with relative sparing of the normal bone 
marrow stem cells. Colony-forming assays can be used to study the effect of 
anti-cancer therapy on clonogenic cells. In AML, in vitro drug sensitivity ap­
peared to be related to the in vivo complete remission r a t e . 4 7 4 9 
In Chapter 2, the cytotoxic effect of Ara-C on leukemic and normal clo­
nogenic cells was investigated. Previous experiments demonstrated increased 
cytotoxicity with prolongation of the exposure t ime. 5 0 Therefore a prolon­
ged (10-day) exposure period was chosen in an attempt to overcome the 
kinetic resistance of slowly cycling leukemic cells. 
Clonogenic assays can also be applied to investigate the effects of 
growth factors on colony-forming cells. Growth factors may recruit cells into 
cycle and thus increase the toxicity of S-phase-specific agents. In Chapter 3 the 
effect of IL-3, GM-CSF, G-CSF, and combinations of these 3 factors was tested 
on blast cells of AML patients. Ara-C sensitivity was tested in the presence of 
weak and strong clonogenic cell growth-promoting hematopoietic factors. 
1 4 I C H A P T E R O N E 
The proliferative behaviour of progenitor cells can be investigated with suici­
de techniques. The described inaccuracy of these techniques made us search 
for new techniques. In Chapter 4, IdUrd was used to develop these techniques. 
The results were compared with the golden standard (3H-TdR suicide tech­
nique). 
The in Chapter 4 developed prolonged IdUrd labeling technique was 
applied in Chapter 5 With this technique, the influence of growth factors on 
the kinetics of leukemic and normal clonogenic cells could be investigated 
over a period of several days. Furthermore, the relation between the fraction 
of cycling CFU-L/CFU-GM and the Ara-C sensitivity was studied to investi­
gate whether recruitment increased the toxicity of S-phase-specific agents. 
The majority of AMLs and up to 50% of the MDSs have chromosomal 
abnormalities.1 1·1 6 To establish the leukemic origin of progenitors more 
accurately, a novel interphase cytogenetic technique was developed to detect 
chromosomal aberrations in clonogenic cells (Chapter 6). 
In Chapter 7, this in situ hybridization (ISH) technique was applied to 
study the clonal origin of AML at progenitor cell level during preleukemic 
phase, active disease, remission, and under in vitro culture conditions. 
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Summary 
We investigated the cytotoxic effect of the cell cycle-specific agent cytosine 
arabmoside (Ara-C) on clonogenic leukemic and normal bone marrow cells. 
To overcome kinetic resistance and to increase cytotoxicity, the cells were 
exposed to Ara-C in liquid culture medium for extended time periods, that is , 
5 and 10 days. Subsequently the number of surviving clonogenic cells was 
determined in a semi-solid assay. All cultures were stimulated with the com­
bination of interleukin 3 (IL-3), granulocyte-macrophage colony-stimula­
ting factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) to 
induce optimal cell proliferation. In comparison to normal clonogenic bone 
marrow cells (granulocyte-macrophage colony-forming units, CFU-GM) 
5-day Ara-C exposure resulted in an equal to a slightly more effective kill of 
leukemic colony-forming cells (CFU-L) The Ara-C dose resulting in 50% 
inhibition (IDso) was 1.6 ± 1 6 χ 10"8 M for CFU-L (n = 9) and 6.7 ± 4.3 χ 
10"8 M for CFU-GM (η = 4 , ρ = 0.096). Prolongation of the Ara-C exposure 
time from 5 to 10 days increased the cytotoxicity towards the majority of the 
leukemic clonogenic cells (ID50: 0.8 ± 0.6 χ IO"8 M) but not towards CFU-
GM (ID50: 5.7 ± 2.8 χ 10"8M). Overall, significantly more leukemic clonoge­
nic cells than normal CFU-GM were killed after 10 days of exposure to Ara-C 
(p = 0.039). These results indicate that leukemic clonogenic cells can be era­
dicated preferentially by prolonged exposure to low dosages of Ara-C in the 
presence of hematopoietic growth factors with relative preservation of the 
normal hematopoietic progenitor cells. 
Introduction 
The population of leukemic blast cells consists mainly of end cells and only a 
minority of stem cells, responsible for the maintenance of the leukemia. ' ·2 In 
leukemic patients the aim of cytotoxic therapy is eradication of these leuke­
mic stem cells with relative sparing of the normal bone marrow stem cells 
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Су tosine arabinoside (Ara-C), a potent antileukemic drug, is included in most 
acute myeloid leukemia (AML) treatment schemes. Its cytotoxic effect is 
thought to be determined mainly by the intracellular synthesis and retention 
of Ara-C tnphoshate (Ara-CTP), which interferes with DNA synthesis.3 For 
that reason Ara-C is preferentially cytotoxic to proliferating cells.4·5 
In vivo, Ara-C is rapidly inactivated to uracil arabinoside (Ara-U),6 so 
that Ara-C chemotherapy consisting of push injections or a few hour of infu­
sion only results in short-term exposure of cells to Ara-C. Because a substantial 
number of leukemic stem cells is non- or very slowly cycling,7"9 it is to be 
expected that these cells are not eradicated by the traditional Ara-C chemothe­
rapy. Evidence for this kinetic resistence was found in our previous experi­
ments. ' °· " In the presence of human placenta-conditioned medium (HPCM) 
as a source of colony-stimulating factor (CSF), clonogenic cells were exposed 
to Ara-C for 1 or 20 h. Even pharmacologically high concentrations of Ara-C 
only marginally affected the colony growth of normal bone marrow cells and 
leukemic blasts, reflecting the low number of cycling cells. ' ° Only when the 
exposure time was prolonged to 5-day liquid incubation or 10-day conti­
nuous exposure in semi-solid medium (cocultivation), complete inhibition 
of granulocyte-macrophage colony-forming units (CFU-GM) and leukemic 
colony-forming units (CFU-L) was observed. ' °· " This indicated that during 
prolonged exposure clonogenic cells traversed the cell cycle. 
With cocultivation, colony growth inhibition and not necessarily 
clonogenic cell kill is tested. ' 2 Furthermore, it is difficult to extend the results 
of the cocultivation test system to the clinical situation, where the outcome of 
chemotherapy does not depend on how many leukemic clonogenic cells can 
be detected at the end of the course but how many clonogenic cells still can 
grow out following cytotoxic drug exposure In this paper, therefore, we pre­
ferred to expose clonogenic leukemic and normal bone marrow cells to Ara-C 
in liquid culture for 5 and 10 days and subsequently assessed the number of 
surviving clonogenic cells in a semi-solid system. This test system would 
allow us to investigate whether prolongation of the Ara-C exposure time 
would lead to an increased toxicity towards CFU-L and how toxic this would 
be to normal CFU-GM. Cells were cultured in the presence of recombinant 
hematopoietic growth factores, which regulate the growth of both normal 
bone marrow cells and leukemic blasts.'3"1 6 Optimal growth was obtained 
with the combination of interleukin 3 (IL-3), granulocyte-macrophage colo­
ny-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor 
(G-CSF). 
We observed that leukemic clonogenic cells were killed significantly 
more than their normal counterparts when they were exposed to Ara-C for 
10 days in the presence of these three growth factors. 
Materials and Methods 
Patients g
o n e m a r r 0 w samples from nine previously untreated AML patients 
were used. According to the French-American-British (FAB) classification,17 
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five patients were classified as M2, three patients as M4, and one 
patient as M5. The samples contained 72%-94% blasts Selected leu­
kemic samples requiring exogenous colony-stimulating factors to 
form aggragates in agar were used. Normal bone marrow was obtai­
ned from four patients undergoing cardiac surgery. Informed con­
sent was given in all cases. 
Bone marrow collection, cryopreservation, and thawing t> n r i p _ 
row was collected in sterile buffered acid-citrate dextrose (pH = 7.0). 
Most of the red blood cells and mature myeloid cells were removed 
by centrifugation on a Ficoll (1.085 g/ml) density gradient (Sigma, 
St Louis, Missouri). One-milliliter vials containing 5-20 χ 106 inter­
phase cells in Iscove's medium (Flow Laboratories, Irvine, Scot­
land), supplemented with 5% fetal calf serum (FCS; HyClone, Lo­
gan, Utah) and 10% dimethylsulfoxide (DMSO), were frozen in 
liquid nitrogen using a temperature-controlled freezer (Kryo 10; 
Planer Biomed, Sunbury, Middlesex, UK) Just prior to the experi­
ment, cells were thawed rapidly in a 37°C waterbath, resulting in a 
cell recovery of >90%. The detailed procedure of freezing and tha­
wing has been described before. ' 8 
Incubation with Ara-C
 M a x l m a l l y 1 0 5 i e u k e m i c and normal bone 
marrow cells per milliliter were suspended in Iscove's medium sup­
plemented with 20% FCS, 50 IU/ml penicillin, and 50 μg/ml strep­
tomycin (Flow Laboratories) and incubated in 15-ml culturing 
tubes (Falcon, Becton Dickinson, Lincoln Park, New Jersey). For our 
test system, optimal concentrations of recombinant human IL-3 
(5 U/ml, kindly donated by Dr Wagemaker, ITRI/TNO, Rijswijk, 
The Netherlands), recombinant human GM-CSF (250 U/ml), and 
recombinant human G-CSF (250 U/ml, both kindly donated by 
Behring, Marburg, Germany) were added to the suspensions. The 
final Ara-C (Upjohn, Kalamazoo, Michigan) concentrations added 
varied from 5 χ 10"9 to 5 χ 10"6 M. Dilutions were prepared from 
freshly thawed Ara-C stock solutions. The drug was checked for 
concentration, purity, and stability by high-performance liquid 
chromatography.6 In each experiment the 100% control growth 
was determined in duplicate. Cell suspensions were placed in an 
incubator (37°C with 5% CO2 and a fully humidified atmosphere) 
for 5 or 10 days After incubation, the cell suspensions were washed 
three times with glucose-phosphate buffer to remove all extracellu­
lar Ara-C. The remaining cell pellet was resuspended in FCS and 
used for clonogenic assay. 
Clonogenic assay
 A f t e r 5 a n d 1 0 d a y s 0 f exposure to Ara-C. the 
suviving numbers of CFU-L and CFU-GM were assessed in a semi­
solid assay. The conditions needed for CFU-L and CFU-GM are iden­
tical. ' 9 Cells suspensions were prepared in Iscove's medium supple-
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mentedwith 20% FCS, 0.3% (w/v) Bacto-Agar (Difco, Detroit, Michigan), 
5 U/ml IL-3, 250 U/ml GM-CSF, and 250 U/ml G-CSF, and duplicates were 
cultured in 3 5- χ 1 O-mm culture dishes (Costar, Cambridge, Massachusetts) 
at 37°C in a fully humidified atmosphere containing 5% CO2. The cell con­
centrations were adapted to previously determined plating efficiencies in 
order to obtain an adequate number of 100-200 aggregates per plate After 10 
days the total number of clusters (5-40 cells) and colonies (>40 cells) was 
counted. A CFU-L aggregate usually consisted of <60 immature cells, where­
as a CFU-GM aggregate mostly contained >200 mature granulocytes and/or 
macrophages.2 0 To evaluate the control survival of clonogenic cells after 5 or 
10 days of liquid incubation, cells were also immediately plated in agar, that 
is, without preincubation. 
Curve fitting -р^
е
 д
г а
_с dose-response curves were fitted with the following 
formula: 
f
«
2=ìTfer 
In this formula a stands for the maximal plating efficiency (100%, measured 
when the cells are incubated without Ara-C) and b for the Ara-C concentration 
at which inhibition is 70%; с represents the slope of the curve. The model was 
fitted according to the Gauss-Newton regression procedure with the use of 
the least squares criteria.2 ' The Ara-C concentrations resulting in 50% inhibi­
tion of clonogenicity (ID50) were calculated from these curves. 
Statistics .pjjg ^
а с а a r e r e
p
r e s e n t e c | a s t h e m e a n ± SD. Group data were com­
pared by Student's t-test. 
Results 
Surv iva l of c lonogenic cel ls d u r i n g l i q u i d i n c u b a t i o n 
Before the liquid incubation test system was employed, we checked whether 
sufficient numbers of normal and leukemic clonogenic cells would be present 
even after incubation periods as long as 10 days. Table 1 presents the number 
of clonogenic cells cultured in agar after 5- or 10-day liquid incubation in the 
presence of IL-3, GM-CSF, and G-CSF, compared to the number seen after 
immediate plating in agar. The number of leukemic aggregates cultured wi­
thout preincubation varied considerably from 7 6 t o 3 0 , 3 7 3 p e r 2 x l 0 5 plated 
cells. The normal bone marrow progenitor cells showed a smaller range: 121-
327 aggregates per 2 χ 105 cells. After 5-day incubation, 25-51,125 aggre­
gates per 2 χ 105 leukemic cells and 166-863 per 2 χ 10 s normal bone mar­
row cells were counted. When the number of aggregates cultured without 
preincubation was considered 100%, the percentage of clonogenic cells pre-
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Survival of clonogenic cells after liquid incubation without Ara-C in the presence of 
IL-3 plus GM-CSF plus G-CSF 
Duration of incubation9 
Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Cell type 
M2b 
M2 
M2 
N12 
M2 
M4 
M4 
M4 
M5 
Normal 
Normal 
Normal 
Normal 
ODays 
23,400c 
195 
14,400 
5298 
76 
30,373 
2840 
95 
1448 
327 
318 
129 
121 
5 Days 
34,600c 
1227 
6020 
2229 
25 
51,125 
18,475 
151 
7535 
289 
863 
166 
621 
(148)" 
(629) 
(42) 
(42) 
(33I 
(168) 
(651) 
(159) 
(520) 
(88) 
(271) 
(129) 
(513) 
10 Days 
16,383° (70)d 
185 (95) 
2863 (20) 
1172 (22) 
15 (20) 
37,325 (123) 
17,760 (625) 
32 (34) 
947 (65) 
89 (27) 
905 (284) 
77 (59) 
313 (259) 
a Cells were plated in agar either directly (= incubation period of 0 days) or after an 
incubation period of 5 or 10 days, 
b Leukemic marrow classified according to FAB classification 
с Absolute number of aggregates (>5 cells) per 2 χ 105 cells, 
d Percentage of aggregates present after 5-or 10-day incubation considering the 
number of aggregates cutured without incubation to be 100% 
sent after 5-day incubation was 33%-651% for the leukemic samples and 
88%-513% for the normal bone marrows. After 10-day incubation, these 
percentages were 20%-625% for the leukemic cells and 27%-284% for the 
normal bone marrow cells. Except one normal bone marrow (no. 11), all 
samples contained lower numbers of clonogenic cells after 10-day liquid 
incubation compared to 5-day incubation. The survival of leukemic and nor­
mal bone marrow clonogenic cells during liquid incubation followed diffe­
rent patterns. Some samples contained more clonogenic cells after 5- and 10-
day incubation than without incubation (nos. 6, 7, 11, and 13). In other cell 
samples (nos. 1, 2, 8, 9, and 12), the number of clonogenic cells after 5-day 
incubation was higher and after 10-day incubation lower than the number 
cultured after immediate plating m agar In sample nos. 3, 4, 5, and 10 the 
number of clonogenic cells decreased with the extension of the incubation 
period. 
E x p o s u r e to A r a - C f o r 5 d a y s 
Five-day exposure to Ara-C in the presence of IL-3, GM-CSF, and G-CSF inhi­
bited the colony growth of leukemic as well as normal bone marrow cells. The 
mean Ara-C dose resulting in 50% inhibition (ID50) oftheCFU-Lwas 1.64 ± 
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Figure 1 The concentrations of Ara-C (χ 108 M) resulting in 
50% inhibition of the survival of clonogenic normal bone 
marrow cells (л = 4) and leukemic blasts (л = 9) exposed to 
Ara-C for 5 and 10 days in the presence of IL-3, GM-CSF, and 
G-CSF. 
normal leukemic 
* = = ? 
5 10 5 10 
exposure time (days) 
- percent survival 
e^¿~^* 
\ \* 
c \ n 
В 
• s days 
α 10 days 
~~^_^ 
Ara-C concentration [M] Ara-C concentration [M] 
Figure 2 Representative examples of Ara-C dose survival curves. The survival percentages are 
expressed asa percentage of two duplicate control cultures. The curves in the left part of the 
figure (2a) were obtained with normal bone marrow cells, whereas the curves in the right part of the 
figure (2b) were obtained with leukemic blasts. The cells were exposed to various concentrations of 
Ara-C for 5 or 10 days in the presence of IL-3, GM-CSF, and G-CSF. 
1.56 χ ΙΟ"8 Μ (η = 9), whereas the mean ID50 value for the normal bone mar­
row cells was 6.74 ± 4.29 χ 10"8 M Ara-C (η = 4). Seven of the leukemic sam­
ples were more sensitive to Ara-C cytotoxicity than the normal bone marrows 
(Fig. 1). Although the leukemic cells tended to be more sensitive to Ara-C 
than the normal cells, the difference was not significant (p =0.096; Table 2). 
E f f e c t of p r o l o n g a t i o n of t h e A r a - C e x p o s u r e t o 10 d a y s 
In order to enable more clonogenic cells to traverse the cell cycle and thereby 
make them more sensitive to Ara-C, the exposure time was extended from 5 
to 10 days. Three out of four normal bone marrow samples showed a slight 
increase in Ara-C sensitivity, whereas one became less sensitive (Fig. 1). 
Overall, however, the cytotoxic effect towards CFU-GM remained about the 
same (mean ID50 values after S-day exposure, 6.74 ± 4.29 χ 10"8 M, com-
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Relation between Ara-C exposure time and cytotoxicity 
Exposure 
time (days) 
5 
10 
CFU-GM 
6.74±4.29b 
5.72 ±2.83 
η 
4 
4 
CFU-L 
1.64±1.56 
0.78±0.56 
η 
9 
9 
Ρ
3 
0.096 
0.039e 
a p-value obtained with Student's t-test. 
b Mean Ara-C concentration (± SD) χ 108 Μ that inhibited 50% of the normal 
bone marrow(CFU-GM) and leukemic (CFU-L) clonogenic cells, 
с Significant. 
pared to 5 . 7 2 ± 2 . 8 3 x 10"8 M after 10-day exposure; Table 2). In Figure 2A, 
representative inhibition curves of normal CFU-GM are plotted, showing an 
equal sensitivity to Ara-C regardless of whether they were exposed to Ara-C 
for 5 or 10 days. 
The sensitivity of leukemic blasts to Ara-C increased substantially in 
seven out of nine patients when the exposure time was prolonged from 5 to 
10 days. The remaining two leukemic samples showed no change in cytotoxi­
city (Fig. 1). For the leukemic samples the mean ID50 value decreased from 
1.64± 1.56x ΙΟ"8 M after 5-day exposure to 0.78 ± 0 . 5 6 χ 10' 8Mafter 10-
day exposure (Table 2). This mean ID50 value of the leukemic samples after 
10-day exposure was significantly different from the ID50 value of the normal 
samples (p =0.039; Table 2 ). As demonstrated in Figure 1, all leukemic sam­
ples became more sensitive than the normal progenitor cells after 10-day 
exposure to Ara-C. This change in sensitivity of the leukemic versus the nor­
mal samples is illustrated in the inhibition curves shown in Figure 2. 
Discussion 
To investigate the effect of Ara-C on leukemic cell populations in vitro, we pre­
fer to evaluate the toxicity of this drug on clonogenic cells, because clonoge­
nic cells (especially the stem cells, which possess self-renewal capacity) are 
responsible for the maintenance of the leukemia.1·2 Ara-C is preferentially 
cytotoxic to proliferating cells.4·5 This means that short-term exposure to Ara-
C will exhibit little or no effect on the non- and very slowly cycling propor­
tion of clonogenic cells. ' ° This kinetic resistance may be overcome by prolon­
gation of the Ara-C exposure time, because per time unit a certain number of 
clonogenic cells are triggered into proliferation cycle. ' Kinetic resistance also 
may be less when cells are stimulated to proliferate by CSF(s). 
Studies performed by other investigators indicated that selected leuke­
mic cells cultured with crude CSF in suspension for up to 238 days still con­
tained clonogenic cells able to form colonies morphologically identical to the 
colonies cultured at the beginning of the incubtion. 2 2 · 2 3 We stimulated nor­
mal bone marrow and leukemic cells optimally with the combination of IL- 3, 
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GM-CSF, and G-CSF for 5 and 10 days in suspension and subsequently asses-
sed the survival of the clonogenic cells. To minimize the influence of endoge-
nously produced CSF in this study, leukemic samples with spontaneous colo-
ny growth were excluded. Both increase and decrease in number of 
aggregates were observed during 10 days of incubation (Table 1 ), confir-
ming earlier observations.22 These patterns could be a reflection of the real 
growth potential or could have been caused by the culture conditions 
Because the suspension cultures were started with low cell concentrations and 
the cell numbers after 5 and 10 days of culture were between 50% and 200% 
of the initial cell numbers (data not shown), overcrowding was not the case. A 
relation between the patterns and the toxic effect of Ara-C was not found. 
Sufficient numbers of colony-forming cells were present even after 10 days of 
incubation (Table 1 ). Therefore, the test system was considered appropriate 
to investigate whether prolongation of the Ara-C exposure time to 10 days 
would result in an increased cytotoxicity towards leukemic clonogenic cells 
and normal progenitor cells. 
When leukemic and normal clonogenic cells were exposed to Ara-C 
for 5 days in the presence of IL-3, GM-CSF, and G-CSF, in most cases the inhi-
bition of CFU-L was higher than the inhibition of CFU-GM, but the difference 
was not significant (Table 2). These results were comparable with the preli-
minary data using HPCM instead of recombinant growth factors. ' ' 
Prolongation of the Ara-C exposure time to 10 days resulted in an increased 
cytotoxicity towards most of the leukemic samples, but not towards the nor-
mal bone marrow cells This implied that exposure to Ara-C for 10 days resul-
ted in a more preferential kill of leukemic clonogenic cells. Two of the nine 
investigated leukemias did not show an increased inhibition when they were 
exposed to Ara-C for 10 days instead of 5 days. It is striking that precisely these 
two leukemias were the most sensitive to the toxic effect of 5-day Ara-C 
exposure and were already inhibited to a much greater extent than the normal 
clonogenic cells. 
Because the cytotoxic effect of Ara-C can be considered as a reflection 
of the proliferative activity, our observation would indicate that normal 
progenitor cells proliferated less than leukemic progenitor cells. An earlier 
report, in which the proliferative state of CFU-L and CFU-GM was measured 
by tntiated thymidine (3H-TdR) labeling, indeed showed that the labeling 
index was higher for the leukemic progenitors.7 An alternative explanation 
for the difference in cytotoxicity between the normal and the leukemic proge-
nitors could be that there were differences in the levels of cytidine kinase and 
cytidine deaminase, thus altering the effective dose of Ara-C to which they 
were exposed. However, in previous experiments the Ara-C fraction left in 
the medium after S days of exposure to 10"6 M Ara-C was a mean of 52% for 
normal CFU-GM and 41 % for CFU-L, whereas no relation was found between 
the residual Ara-C concentration and the ID50 values (unpublished observa-
tions) . 
Because selected leukemic samples were used that formed aggregates 
only when they were stimulated with CSF, we have not proven yet whether 
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the same differential kill applies for in vitro spontaneously growing leukemias 
or leukemias not forming aggregates in vitro. Obviously, the nongrowing leu-
kemias cannot be tested in this clonogenic assay system, whereas the effect on 
spontaneously growing leukemias is under current investigation. 
Recently, selective kill of leukemic myeloblasts versus normal CFU-
GM after only 96-h exposure to Ara-C was reported in a study investigating 
the possibilities for ex vivo bone marrow purging.24 However, in that study the 
bone marrow was exposed to Ara-C in the presence of deoxycytidine, which 
preferentially protects normal CFU-GM from the toxicity of Ara-C.25 
Moreover, the cells were exposed to Ara-C in a culture medium lacking CSF. 
This unfavorable condition also contributed to the observed selective kill 
because after 96-h incubation the control growth of CFU-L dropped to 28%, 
whereas normal CFU-GM control growth remained 100%. 
The cells cultured after 10 days of liquid incubation can be considered 
as clonogenic cells with self-renewal capacity.22·23·26 Those cells and their 
susceptibility to Ara-C play an important role in the clinical outcome of anti-
leukemic treatment. Patients with low m vitro numbers of blast progenitors 
with self-renewal capacity had a significantly greater chance of a successful 
remission induction.27 Moreover, in a study where leukemic blasts in suspen-
sion were exposed to Ara-C for 7 days and replated in methylcellulose to 
assess the surviving clonogenic cells, a significant relation between Ara-C 
ID90 values and a successful remission induction was found.23 
It has been reported that the balance between self-renewal and termi-
nal division can be influenced by culturing leukemic cells in the presence of 
IL-3, GM-CSF, or G-CSF alone.27 The responses varied for the different tested 
leukemias, and the influence on this balance in normal bone marrow was not 
described. When leukemic cells were cultured in the presence of a particular 
growth factor that favored for self-renewal, an increased sensitivity to Ara-C 
was noticed.28 An alternative to the optimal stimulation of all leukemic clo-
nogenic cells with the combination of IL-3, GM-CSF, and G-CSF may be to 
determine for individual leukemias the single or the combination of recom-
binant growth factor(s) that more selectively stimulates the leukemic stem 
cells. Growth factors with relatively little stimulatory effect on normal stem 
cells are of particular interest. In the near future, leukemic patients may be 
treated with a therapy consisting of these individually determined growth 
factors combined with low dosages of Ara-C (or other cell cycle-specific 
agents). The dosages of Ara-C needed in this study for an effective kill were in 
the same range as the plasma concentrations reached with in vivo low-dose 
Ara-C administration.29 Low-dose Ara-C therapy can be given to outpatients 
and usually causes only minimal extramedullary toxicity. This treatment 
schedule has already been applied in patients with myelodysplastic syn-
dromes who received low-dose Ara-C in combination with GM-CSF.30 
A theoretical application of this treatment modality could be ex vivo 
purging of bone marrow with the combination of Ara-C and growth factors. 
Because this implies a 10-day culture of the bone marrow, a major concern 
would be the survival of the hematopoietic stem cells in this liquid culture 
system (in contrast to the 'natural' environment of the patient). As an alterna-
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tive, combined Ara-C and growth factor exposure in a long-term bone mar­
row culture (LTBMC) system could be considered. This system has proven to 
retain repopulatmg ability for at least 11 days,31 and the system by itself 
seems to favor the maintenance of normal hematopoiesis 3 2 
In short, our results show that by prolonged exposure to low-dose 
Ara-C in the presence of the hematopoietic growth factors IL-3, GM-CSF, and 
G-CSF, more leukemic than normal bone marrow clonogenic cells with self-
renewal capacity are killed. 
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Summary 
In vivo, growth factors are currently investigated for their capacity to trigger 
leukemic stem cells into cycle and thus overcome kinetic drug resistance. In 
this study, the susceptibility of leukemic clonogenic cells to individual 
growth factors was related to cytosine-arabinoside (Ara-C) sensitivity The 
effects of interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and com­
binations of these recombinant hematopoietic factors were tested on blast 
cells of nine acute myeloid leukemia (AML) patients. Growth factor responses 
were assessed in semi-solid clonogenic assay and in a 10-day liquid culture 
followed by clonogenic assay. Heterogeneity in growth factor response was 
observed in both test systems, resulting in a variable pattern for individual 
leukemias. In the majority of cases (six of nine) the response patterns in the 
semi-solid and liquid cultures were divergent. To test the Ara-C sensitivity, 
leukemic blasts were exposed in liquid to various concentrations of Ara-C in 
the absence and presence of preselected growth factors. After 10 days, the 
number of surviving leukemic colony-forming cells (CFU-L) was assessed. 
Exposure to Ara-C in the presence of optimal stimulatory factor(s) resulted in 
a 3- to 1000-fold increase of the Ara-C toxicity in seven patients. The Ara-C 
concentrations resulting in 50% inhibition of clonogenicity (ID50) were 
0.48-123 χ 1 0 8 M Ara-C in the absence of stimulatory growth factors, versus 
only 0.12-0.40 χ Ι Ο 8 M Ara-C in the presence of these factors. In two 
patients, addition of one or more factors neither increased the number of 
CFU-L in liquid nor enhanced the Ara-C toxicity. Even in the absence of 
growth factors the ID50 values in these cases were as low as 0.20 and 0.28 χ 
1 0 8 M Ara-C and in the same range as the ID50 values observed with maxi­
mum growth factor stimulation in the other seven patients. These results indi­
cate that Ara-C cytotoxicity can be enhanced by individually selected, clo­
nogenic cell growth-promoting hematopoietic factors. 
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Introduction 
A substantial number of leukemic myeloblasts are non- or very slowly 
cycling. ' 4 These cells may escape antileukemic treatment with cell cycle-spe-
cific drugs like cytosine-arabinoside (Ara-C). This phenomenon, referred to 
as kinetic resistance, is considered to be an important mechanism for Ara-C 
resistance in acute myeloid leukemia (AML) and can be distinguished from 
metabolic resistance.5 Previous in vitro studies showed that prolongation of the 
Ara-C exposure time up to 10 days substantially increased the toxicity of Ara-
C towards leukemic clonogemc cells 6 · 7 During prolonged exposure, tempo-
rarily noncycling cells were allowed to enter the proliferation cycle and slow-
ly cycling cells apparently became more sensitive to Ara-C.8,9 By this design, 
kinetic resistance was at least partially overcome. An additional option for cir-
cumventing kinetic resistance could be proliferation induction. Multiple stu-
dies show that both in vitro and in vivo the growth of myeloid leukemic blasts is 
regulated by the same colony-stimulating factors that control normal hema-
topoiesis.10"24 Particularly interleukin-3 (IL-3), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating 
factor (G-CSF) can stimulate the proliferation of leukemic myelo-
blasts. ' 2 · I 5 , ' 7 · 2 0 · 2 2 · 2 4 Therefore, we investigated whether stimulation of leu-
kemic clonogenic cells with these growth factors could overcome the kinetic 
resistance to Ara-C. For individual leukemias the response patterns to IL-3, 
GM-CSF, G-CSF, and combinations of these factors were determined. Factor 
responsiveness was tested in a semi-solid system and in a liquid culture, follo-
wed by clonogenic assay. Since previous experiments showed that the toxici-
ty of clinically relevant Ara-C dosages was tested most optimally by a 10-day 
Ara-C exposure,6·7 this test system was applied to evaluate the toxic effect of 
the combined Ara-C and growth factor treatment. 
Our results show that the kinetic resistance of leukemic clonogenic 
cells to Ara-C can be decreased by stimulation with individually adapted 
hematopoietic growth factors. 
Materials and Methods 
Patients g o n e m a r r 0 w samples from nine previously untreated AML patients 
(five females, four males) were tested. The median patient age was 53 years 
(range 16-66). The diagnosis according to the French-American-British 
(F AB) classification was M2(n = 5), M4(n = 2), MS(n= 1) andM6 (n= l ) . 2 5 
The samples contained median 68% blasts (range 28-94). Normal bone mar-
row was obtained from five patients undergoing cardiac surgery. Informed 
consent was given in all cases. 
Bone marrow collection, cryopreservation, thawing
 B o n e marrow was collec-
ted in sterile buffered acid-citrate dextrose (pH=7.0). The majority of the red 
blood cells and mature myeloid cells were removed by centrifugation on 
Ficoll (1.085 g/ml, Sigma, St. Louis, Missouri, USA). The cells were cryopre-
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served in 1 -ml vials in liquid nitrogen with a temperature-controlled freezer 
(Kryo 10; Planer Biomed, Sunbury, Middlesex, UK). Vials contained 5-20 χ 
106 interphase cells suspended in Iscove's medium (Flow Laboratories, 
Irvine, Scotland), supplemented with 5% fetal calf serum (FCS; HyClone, 
Logan, Utah, USA) and 10% dimethylsulfoxide (DMSO). Just prior to the 
experiment, cells were thawed rapidly in a 37°C waterbath resulting in a cell 
recovery of >90%. The detailed procedure of freezing and thawing has been 
described before.2 6 
Human recombinant growth factors
 H u m a n r e c o m b i n a n t I L _ 3 w a s k m d l y 
donated by Sandoz BV (Uden, The Netherlands) Human recombinant GM-
CSF and G-CSF, were a kind gift from Behring (Marburg, Germany). Single 
factors and combinations were added to both the semi-solid cultures and the 
liquid cultures at final concentrations of 40 ng/ml, 5 ng/ml, and 5 ng/ml 
respectively. These concentrations resulted in plateau stimulation. 
С onogemc assay (C U) £
е
ц
 S U S p e n s i o n s were prepared in Iscove's medium 
supplemented with 20% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin 
(Flow Laboratories), and 0.3% (w/v) bacto-agar (Difco, Detroit, Michigan, 
USA). To determine the effects of recombinant growth factors on leukemic 
and normal colony-forming cells (CFU-L/GM), no factor, the single factors 
and combinations of two or three factors were added to the semi-solid assay. 
All samples were exposed to the same panel of growth factors. Duplicates 
were cultured in 35- χ 10-mm culture dishes (Costar, Cambridge, Mas­
sachusetts, USA) at 37°C in a fully humidified atmosphere containing 5% 
CO2. In order to obtain an adequate number of about 200 aggregates/dish, 
2 χ 103-2 χ 105 cells were plated After 7-10 days, clusters (5-40 cells) and 
colonies (>40 cells) were counted. The leukemic samples all had a high pla­
ting efficiency and the uniformly appearing CFU-L aggregates consisited of 
<60 immature cells. Compared to the leukemic samples, the plating efficien­
cy of the normal BM samples was lower, whereas the CFU-GM aggregates 
usually contained >200 mature granulocytes and/or macrophages. 
Liquid culture Maximally ю 5 cells/ml were suspended in tubes (Falcon, 
Becton Dickinson, Lincoln Park, New Jersey, USA) containing Iscove's me­
dium supplemented with 20% FCS, 50 IU/ml penicillin, and 50 μg/ml strep­
tomycin. Stimulation by IL-3, GM-CSF, and G-CSF was tested by adding no 
factor, the single factors, and combinations of two or three factors to the 
medium. All samples were exposed to the same panel of growth factors. The 
cell suspensions were cultured in an incubator (3 7°C, 5% CO¿ in air and fully 
humidified atmosphere) for a period of 10 days. Thereafter, cells were wash-
ed with glucose-phosphate buffer and the number of CFU was assessed by 
clonogemc assay stimulated with the combination of IL-3, GM-CSF, and 
G-CSF (see clonogemc assay). 
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ra- exposure т ^ ц ^ е т ^ cells were exposed to Ara-C (Upjohn, Kalamazoo, 
Michigan, USA) during a 10-day liquid culture with or without growth fac­
tor^) . The final added concentrations varied from 10"1 0 to 5 χ IO"5 M Ara-C. 
Dilutions were prepared from freshly thawed Ara-C stock solutions. The drug 
was checked for concentration, purity, and stability by high-performance 
liquid chromatography (HPLC).27 After the exposure, cells were washed 
three times to remove all nonphosphorylated cellular and extracellular Ara-C. 
Subsequently, the number of surviving CFU-L was determined by clonogenic 
assay in the presence of the combination of IL-3, GM-CSF, and G-CSF (see 
above) In nine experiments, after the 10-day exposures, the remaining Ara-C 
concentrations in the suspensions were determined by HPLC. 
Curve fitting and statistics
 T Q fo ± е A r a _ c d o s e r e s p o n s e c u r v e S i ± e f o l b . 
wing formula was used: 
In this formula α stands for the maximal plating efficiency (100%, measured 
when the cells are incubated without Ara-C) and b for the Ara-C concentration 
at which inhibition is 70%; с represents the slope of the curve. The data were 
fitted according to the Gauss-Newton regression procedure with the use of 
the least squares criteria.28 The Ara-C concentrations resulting in 50% inhibi­
tion of clonogenicity (ID50) were calculated from these curves. 
Results 
G r o w t h responses in semi-sol id cu l tures 
To assess the responses of leukemic clonogenic cells to growth factors, blasts 
from nine AML patients were cultured in semi-solid assays both in the absence 
and presence of IL-3, GM-CSF, G-CSF, and combinations of these factors. The 
mean number of cultured aggregates per 2 χ IO5 plated cells is depicted in 
Figure 1. In all cases, the cluster-to-colony ratio exceeded 5. Mostly, a pattern 
of large (maximum cluster size, 40 immature cells) or small (maximum clus­
ter size, 20 immature cells) clusters was observed. Spontaneous growth in the 
absence of exogenous growth factors was observed in three cases (nos. 1,4, 
5). In five cases (nos. 1,2,6,7,8) G-CSF was the best single stimulator. In the 
other four cases similar responses to either single factor (nos. 3, 4) or an 
almost equal stimulation with two single factors and a lower aggregate num­
ber when cultured with the third single factor (nos. 5,9) was found. In gene­
ral, the number of aggregates increased when more than one recombinant 
factor was added. Synergism between two and/or three factors was observed 
in seven cases, for example between IL-3/G-CSF, GM-CSF/G-CSF, and 
IL-3 /GM-CSF/G-CSF in case 6. 
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Figurai gf
 m n e д^/iL patients and five normal bone marrow donors, the growth factor responses 
of blasts and normal bone marrow cells were determined in semi-solid and liquid cultures. In the 
semi-solid culture cells were exposed to: no factor, IL-3, GM-CSF, G-CSF, and combinations of these 
factors In the liquid cultures cells were exposed to the same panel of growth factors for 10 days fol­
lowed by semi-solid assay stimulated with the combination of IL-3, GM-CSF, and G-CSF The respon­
ses are expressed as the number of CFU-L/GM per 2 χ IO5 'input' cells. The left part ol each diagram 
represents the data obtained in semi-solid cultures The rightpartof each diagram shows the results 
obtained in the liquid cultures Notice that the absolute number of CFU substantially differs between 
individual patients. Response patterns of individual AML cases are presented in separate diagrams. 
Results obtained with normal bone marrow cells are combined and expressed as mean (±SEM) in 
one diagram 
G r o w t h r e s p o n s e s i n l i q u i d c u l t u r e s 
The growth factor responses in the liquid cultures are shown for each indivi­
dual patient in Figure 1. In all cases, aggregates were detectable in the semi­
solid assay after 10-day liquid culture without colony stimulating factor 
(CSF). Incubation with a single factor showed in one case (no. 8) that IL-3 was 
the most effective stimulator, in two cases GM-CSF (nos. 4 and 5), and in one 
case G-CSF (no. 6). Similar responses to all three single factors or almost equal 
results with two single factors and lower aggregate numbers in the presence 
of the third single factor were seen in the other five cases. In contrast to the 
responses in the agar cultures, addition of more than one growth factor did 
not tend to increase the number of colony-forming cells. Evident synergism 
between two and/or three factors could only be observed in case 6. The num­
ber of aggregates obtained by maximum stimulation during liquid culture 
was 139 ± 72% (mean ± 95% confidence interval) of the number of CFU-L 
obtained when cells were directly cultured in semi-solid. 
Comparison of the response patterns of individual patients revealed 
that in six of the nine cases the growth responses in semi-solid and liquid cul­
ture were divergent Either the single factor which best supported the clo-
nogenic cell growth had changed (as in case 8, where G-CSF gave the best sti­
mulus in the semi-solid assay and IL-3 the best during liquid culture) or 
prominent differences had disappeared (for example case 2, in which IL-3, 
GM-CSF, and G-CSF revealed similar numbers after liquid stimulation, 
whereras the aggregate numbers in the primary culture were quite different). 
Enhancement of Ara-C toxicity by stimulation 
with growth factors 
To test our hypothesis that proliferation induction enhanced cytotoxicity, 
the leukemic blasts were exposed to Ara-C for 10 days in the absence and pre­
sence of preselected factors (Table 1). Factors, which caused the most pro­
nounced differences in stimulation during the liquid cultures, were prefe­
rentially chosen. 
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Enhancement of Ara-C toxicity by proliferation induction 
Patient 
Added factor3 
No factor 
IL-3 
IL-3+G-CSF 
No factor 
GM-CSF 
G-CSF 
IL-3+GM-CSF 
G-CSF 
GM-CSF 
No factor 
G-CSF 
IL-3+GM-CSF+G-CSF 
No factor 
IL-3 
GM-CSF+G-CSF 
No factor 
GM-CSF 
G-CSF 
No factor 
IL-3+GM-CSF+G-CSF 
IL-3 
No factor 
GM-CSF 
Control growth11 
9720 
8480 
2400 
3080 
20600 
70 
740 
40 
580 
400 
900 
2810 
650 
8750 
86000 
2480 
1100 
3190 
230 
1240 
1400 
80 
660 
ID50 value0 
0.28 
0.16 
0-36 
176 
0.40 
047 
0.16 
1.31 
0 23 
58 9 
2.54 
032 
123 
0 26 
012 
0.20 
0.11 
0.07 
0.48 
0.28 
0.13 
3.22 
033 
a Growth factor(s) added to the liquid culture. 
b CFU-L number per 2 χ 105 'input' cells, assessed in duplicate after 10-day liquid culture in the 
absence of Ara-C. 
с Ara-C concentration χ 10s M, that inhibited 50% of the CFU-L growth. The values were calculated 
from survival curves constructed after 10-day exposure to various concentrations of Ara-C. 
In seven cases (nos. 2, 3,4, 5, 6, 8, 9) growth factor (s) stimulated the leuke­
mic clonogenic cells in liquid and a substantial increase of Ara-C toxicity was 
observed. In individual cases, better stimulation correlated with higher Ara-C 
sensitivity. The Ara-C dose survival curves of two representative examples 
(nos. 5 and 6) are shown in Figure 2. In case 5, G-CSF enhanced Ara-C toxici­
ty. The ID50 value was 2.54 χ 10'8 M Ara-C corn-pared to 58.9 χ 1 (Г8 M Ara-C 
in the absence of any factor. An even better stimulation with the combination 
of IL-3, GM-CSF, and G-CSF further increased the Ara-C sensitivity. The LD50 
value of 0.3 2 χ 10"8 M Ara-C was 18 0-fold lower than the ID5 0 value observed 
in the absence of CSF. A similar increase in Ara-C sensitivity was observed in 
case 6. When stimulated with IL-3 alone and the combination of GM-CSF and 
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Figure 2 д
г а
_с dose survival curves of patients 1,5, and 6. 
For a period of 10 days, cells were exposed to various 
concentrations of Ara-C in the presence of the indicated 
growth factor(s). Subsequently, the number of surviving 
CFU-Lwas determined by clonogenic assay stimulated with 
the combination of IL-3, GM-CSF, and G-CSF. The CFU-L 
survival was expressed as a percentage of control cultures. 
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G-CSF respectively, the ID50 value decreased from 123 χ 10"8 M Ara-C in the 
absence of growth factor to 0.26 χ ΙΟ"8 M Ara-C in the presence of IL-3 and 
0.12 χ 10"8 M Ara-C in the presence of GM-CSF and G-CSF. Thus, with this lat­
ter combination of factors, a 1000-fold enhancement of Ara-C toxicity was 
achieved. Overall, stimulation with recombinant growth factors resulted in a 
decrease of the median Ara-C LD50 values from 3.22 (range 0.47-123) to 
0.23 (range 0.12-0.40) χ \0S M. In individual patients a 3- to 1000-fold 
increase of Ara-C toxicity was observed in the presence of growth factor (s). 
In two cases (nos. 1 and 7) addition of growth factor(s) did not in­
crease the number of CFU-L in liquid. In these cases growth factors could not 
enhance the Ara-C toxicity, as shown by the representative Ara-C survival cur­
ves of patient 1 (Fig. 2). Even in the absence of growth factors the ID50 values 
of these two patients were as low as 0.2 8 and 0.2 0 χ 10 "8 M Ara-C respective­
ly. These values were in the same range as the ID50 values observed with 
maximum growth factor stimulation in the other seven patients. 
A r a - C c o n c e n t r a t i o n d u r i n g 1 0 - d a y l i q u i d c u l t u r e 
Ara-C can be inactivated to uracil arabinoside (Ara-U),29 particularly in sus­
pensions with a relatively high cell concentration.6 To minimize this deami-
nation, cell concentrations of less than 105/ml were used. With these relative­
ly low cell concentrations no significant decrease in Ara-C concentration 
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could be detected at the end of the 10-day culture. In the suspensions to which 
initially 1 χ 10"6 M Ara-C was added, the remaining concentration was 0.96 ± 
0.11 χ 10"6 M Ara-C (mean ± 95% confidence interval, η = 9). 
Discussion 
In the present study we investigated the potential role of IL-3, GM-CSF, and G-
CSF to overcome the kinetic resistance of AML blasts to Ara-C. We focused our 
investigations on the clonogenic subpopulation of the leukemic blasts, since 
these clonogenic cells are held responsible for the maintenance of the leuke­
mia. 8 · 9 
In nine leukemias the response to IL-3, GM-CSF, G-CSF, and combina­
tions of these factors was investigated in semisolid culture. As already no­
ticed by others, 1^ .17,20,24
 a
 remarkable diversity in response was observed 
(Fig. 1) and no evident relationship between response pattern and FAB type 
was seen. Synergism between 2 or 3 factors was observed in the majority of 
cases, most often between G-CSF and one or two other factors. The response 
patterns in liquid cultures were also determined (Fig. 1). Heterogeneity in 
response was again observed. In the majority of cases (six of nine) the respon­
ses to growth factors in liquid cultures were divergent from those in the semi­
solid cultures. These data corroborate those of a previously reported study,2 0 
but contradict another. 2 4 It is possible that in the liquid cultures hierarchically 
more immature progenitor cells are cultured, compared to more mature 
progenitors in the semisolid culture. 2 0 · 3 0 These distinct progenitors may have 
different biological properties, which may explain the observed discrepancy. 
The marked variation in response to IL-3, GM-CSF, and G-CSF observed in 
leukemias is in contrast with the reported uniform response of normal hema­
topoietic progenitors. ".12,16,19 γ ^
ε
 studied the growth factor response of 
normal myeloid-macrophage progenitor cells (CFU-GM) and found identical 
response patterns for five different normal bone marrows tested (Fig. 1). 
Surface-marker studies suggest that leukemic clonogenic cells originate at dif­
ferent maturation stages of hematopoiesis.3 ' The heterogeneous response of 
leukemias, therefore, may reflect the position at which the leukemic cells are 
arrested. 
Based on previous results,6·7 the possible enhancement of Ara-C toxi­
city towards leukemic clonogenic cells by growth factors was studied during a 
10-day Ara-C exposure experiment. The growth factors were co-incubated to 
achieve optimal stimulation during the whole drug exposure period. Since 
Ara-C inactivation is cell concentration dependent,6 the cell concentration in 
the test system was intentionally lowered to less than 105 cells/ml. Under this 
condition, on average only 4% of the Ara-C was deaminated during the 10-
day liquid culture. In seven out of nine tested cases, growth factors increased 
the number of leukemic clonogenic cells during the liquid cultures when 
compared to unstimulated cultures. In all these cases, a more effective stimu­
lation corresponded with an increase of Ara-C toxicity (see Table 1 ). Overall, 
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the ID50 values were 3- to 1000-fold lower in case of optimal stimulation. In 
the other two cases, growth factors were not able to increase the clonogenici-
ty during liquid culture, and the Ara-C toxicity was not enhanced (Table 1 ). In 
the absence of exogenously added growth factors, these two leukemias were 
already extremely sensitive to Ara-C. The ID50 values were equal to the values 
observed after maximal stimulation in the other seven leukemias. One of 
these two leukemias showed spontaneous growth in the semi-solid culture, 
suggesting autocrine colony-stimulating factor production or autonomous 
proliferation. This may explain the high toxicity of Ara-C in the absence of 
exogenous colony-stimulating factors. In case of optimal stimulation, rela­
tively low Ara-C concentrations were sufficient to eradicate the leukemic 
clonogenic cells in all nine tested leukemias. In vivo, these Ara-C levels can be 
reached in the plasma of patients treated with subcutaneously administered 
low-dose (20 mg/m 2 /d) Ara-C.32 
Cells may escape Ara-C toxicity by kinetic or metabolic resistance or a 
combination of both. These mechanisms are reported to be of clinical impor­
tance in AML.4·5 Seven of the nine tested leukemic samples showed increased 
Ara-C cytotoxicity after stimulation with growth factors. We may conclude 
that in these leukemias kinetic resistance was the major reason these blasts 
were relatively insensitive to Ara-C toxicity. If metabolic resistance had been 
more important, no substantial increase in toxicity would have been observed 
after recruitment with growth factors. 
Several other papers reported that growth factors can enhance the 
cytotoxic effect of cell cycle-specific agents like Ara-C and hydroxyurea 
towards leukemic cells.3 3"3 8 In these studies, AML blasts were exposed to the 
drugs either in the presence of a growth factor or after prestimulation. In con­
trast to our study, usually only one factor was investigated and the tested 
growth factor was not selected on the basis of individual responsiveness. 
Therefore, the growth factors used in these studies may not have been the 
most optimal stimulus for each tested leukemia. Moreover, the drug exposure 
time was relatively short, ranging from 3 to 24 h. The Ara-C concentrations 
tested were relatively high, varying from ΙΟ"7 M to 10~3 M. Even with these 
pharmacologically very high Ara-C concentrations, which are usually not 
reached for prolonged periods in the clinical situation,3 2 a complete inhibi­
tion of CFU-L was never obtained. This suggests that these incubation periods 
were too short to fully eradicate the leukemic clonogenic cells. These results 
corroborate our data from earlier experiments, showing that during relatively 
short exposure periods of 1 h, 24 h, or 5 days, concentrations of at least 
ΙΟ"
5
 M Ara-C were necessary to inhibit CFU-L growth completely.6 In the 
study of Miyauchi et al. cells of two patients were exposed to Ara-C in the pre­
sence of individually adapted growth factors over a longer period (7 days).3 8 
However, the choice of the added factors was not based on the response in 
liquid, but on the shift from terminal division (methylcellulose) to self-rene­
wal (suspension). No relation between the response in liquid (that is, an 
increase in CFU-L number) and the Ara-C sensitivity was found. Only when 
factors relatively favored self-renewal, a maximally twofold increased sensi-
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tivity to Ara-C was observed. The calculated ID90 values of 0.2-0.6 χ ΙΟ"6 M 
Ara-C were about 10 times higher than observed with the 10-day exposure 
we applied. 
The potential risk of the clinical application of growth factors may be 
proliferation induction of the normal hematopoietic stem cells. In combina­
tion with Ara-C the consequence could be an increased toxicity towards these 
cells resulting in prolonged hypoplasias. In vitro and in vivo data thus far suggest 
that in the presence of growth factors the toxicity of Ara-C towards normal 
progenitor cells is not higher than the toxicity observed with Ara-C 
alone. 3 7 · 3 9 · 4 0 We found that 10-day Ara-C exposure in the presence of the 
combination of IL-3, GM-CSF, and G-CSF resulted in a preferential kill of the 
leukemic versus the normal clonogenic cells.7 Still, more studies in this direc­
tion need to be performed. 
Several pilot studies have investigated the potential value of GM-CSF 
to enhance the cytotoxic efficacy of remission induction therapy in AML.41 
Considering the data presented, it seems less justified to treat all patients with 
the same factor, regardless whether their leukemia can be stimulated with 
that factor or not. Instead, it appears that growth factor(s) should be selected 
individually so that in AML patients recruitment of leukemic clonogenic cells 
can be obtained with optimal stimulatory factor(s). In about 80% of the AML 
cases, CFU-L can be cultured in vitro. This indicates that the majority of AML 
patients can be evaluated for their in vitro growth response. Further clinical 
studies have to prove whether the in vitro recruitment data reflect the in vivo 
biology. 
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Summary 
In vitro suicide by tntiated thymidine (3H-TdR), hydroxyurea (HU), or cytosi-
ne arabinoside (Ara-C) is assumed to reflect the proportion of colony-for­
ming cells in S-phase at the time of exposure. However, these techniques are 
not always accurate. Nonradioactive iododeoxyuridine (IdUrd) is incorpora­
ted into DNA during S-phase and can be detected by monoclonal antibodies. 
In the present study, a new IdUrd application was developed to investigate the 
kinetics of hematopoietic progenitor cells. After incubation with IdUrd, colo­
ny-forming cells were cultured in semi-solid assay. An immunoperoxidase 
staining protocol was developed to detect IdUrd in cells of colonies in agar. 
Colony-forming cells in S-phase during the IdUrd exposure were postulated 
to give rise to IdUrd"1" colonies, whereas non-S-phase cells would generate 
IdUrd" colonies. Toxicity, sensitivity, and IdUrd inactivation studies indica­
ted that progenitor cells could safely be pulse-labeled for 2 hours with 40 μΜ 
IdUrd, whereas prolonged labeling with 1 μΜ IdUrd was at least feasible for 5 
days. 
Molt-4 cells and normal bone marrow cells were used to compare 
IdUrd pulse-labeling with 3H-TdR suicide. Part of the Molt-4 cells were enri­
ched for Gj - and S-phase cells by counterflow centrifugation. The bone mar­
row cells were either unstimulated or stimulated with growth factors. As a 
result, the accuracy of both techniques could be tested in populations with 
different quantities of S-phase cells. Wide confidence intervals of the suicide 
technique contrasted the small confidence intervals obtained with IdUrd 
pulse-labeling. For instance, the fraction of Molt-4 cells with 27.8% S-phase 
cells contained 17.7% (confidence interval -8.2 to 43.6%) clonogenic cells in 
S-phase when determined with 3H-TdR suicide. Of this fraction, the percen­
tage of clonogenic cells in S-phase was 30.6% with a confidence interval of 
25.5 to 36.2% when determined with IdUrd pulse-labeling. In our hands, the 
IdUrd pulse labeling was more accurate than the 3H-TdR suicide technique. 
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Thus far, kinetic studies of progenitors have been limited to the determina­
tion of the fraction of S-phase cells by suicide techniques. By prolonged IdUrd 
labeling, it is now possible to determine the proliferating fraction of progeni­
tor cells. 
Introduction 
Normal and leukemic progenitor cells can be cultured in vitro by semisolid 
assay. ' This enables kinetic studies of these cells. Insight into the proliferative 
behaviour of progenitors will help to understand the biology of the hemato­
poietic system under physiologic and pathological conditions. Furthermore, 
therapeutic interventions, such as exposure to cytostatic drugs or growth fac­
tors, can be evaluated. The proliferative status of progenitors can be studied in 
vitro by suicide techniques.2 , 3 After short-term exposure to 3H-TdR, HU, or 
Ara-C, the loss of progenitor cells is determined by colony-forming assay. The 
fractional reduction in cloning efficiency is considered to reflect the propor­
tion of colony-forming cells in S-phase at the time of exposure. The estima­
tion of progenitors in S-phase by suicide techniques may not always be accu­
rate. 2 · 4 · 5 It has been reported that non-S-phase cells, probably late G[ cells, 
can take up 3H-TdR and eventually will be killed.4·5 Nevertheless, the com­
monly applied 3H-TdR suicide seems to be the most reliable of the available 
techniques.4 
Previously, IdUrd has become available for kinetic studies. This non­
radioactive thymidine analog is incorporated into DNA during S-phase and 
can be detected by anti-IdUrd antibodies.6·7 Using flow cytometry (FCM) or 
immunocytochemistry, S-phase fractions of both normal and malignant cells 
have been determined 8~ ' 2 
To our knowledge, proliferation of hematopoietic progenitors has not 
been studied with IdUrd. The present study was designed to develop a new 
IdUrd technique to investigate the kinetic behaviour of colony-forming cells. 
During IdUrd exposure, only progenitor cells in S-phase will incorporate 
IdUrd into their DNA. Subsequently, when a colony-forming assay is perfor­
med, a single progenitor cell will form one colony. Cell division is expected to 
result in the distribution of parental DNA over the daughter cells. Therefore, 
detection of incorporated IdUrd in the cells of a particular colony will indicate 
that it originated from a colony-forming cell that has been in S-phase during 
the labeling period. Colony-forming cells not in S-phase during exposure will 
give rise to IdUrd" colonies. The fraction of progenitor cells in S-phase can be 
determined by pulse-labeling. The total proportion of cycling progenitors 
can be assessed after a prolonged labeling period. 
Labeling of cells with 10 μΜ IdUrd for 30 minutes proved to be opti­
mal for kinetic analysis by FCM.8·9· ' 3 With FCM, cells are analyzed immedia­
tely after labeling. As a result, dilution of the IdUrd signal due to cell division 
occurs infrequently. In contrast, IdUrd"1" colonies derive from labeled clo-
nogenic cells that have divided several times to form a colony. To prevent that, 
the IdUrd signal will become undetectable, the concentration used to pulse-
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label progenitors should be sufficiently high, and the labeling period as long 
as theoretically justified. 
A 5 2% reduction in myeloid colonies was observed in a study in which 
normal bone marrow was incubated with 5 μΜ IdUrd for 24 hours. 1 4 IdUrd 
can be catabohzed to 5-iodouracil (IUra) and further degradated.1 4 There­
fore, toxicity and IdUrd inactivation were considered to be major limitations 
for prolonged labeling. 
In the present study, sensitivity, toxicity, and IdUrd inactivation were 
evaluated to determine the optimal concentration for pulse and prolonged 
labeling. A previously published protocol developed for immunological 
detection of IdUrd by FCM was improved and adjusted for application on agar 
cultures. ' 3 Comparative studies with 3H-TdR suicide were performed to esta­
blish the accuracy of IdUrd pulse-labeling. 
It appeared that the fraction of colony-forming cells in S-phase can be 
determined more accurately with IdUrd pulse-labeling than with 3H-TdR 
suicide. Moreover, prolonged IdUrd labeling may create the ability to assess 
the fraction of proliferating progenitors. 
Materials and Methods 
Bone marrow collection, cryopreservation, and thawing м
о г г п а
] hone mar­
row cells were obtained from healthy bone marrow donors. Informed con­
sent was given in all cases. The cells were collected in sterile buffered acid-
citrate dextrose (pH=7.0) and enriched for clonogenic cells by flotation 
centnfugation ' 5 In short, cells were mixed with Percoli (Pharmacia, Uppsa­
la, Sweden) to obtain a density of 1.085 g/ml. From this suspension, 15 ml 
was layered under 30 ml of a 1.067 g/ml Percoli solution with S ml Hanks' 
balanced salt solution (HBSS) (Flow Laboratories, Irvine, Scotland) on top of 
it. After centrifugation, the cells with a density of < 1.067 g/ml were collected 
and frozen in liquid nitrogen using a temperature-controlled freezer (Kryo 
10; Planer Biomed, Sunbury, Middlesex, UK). Each vial contained 5 χ IO6 
cells in Iscove's modified Dulbecco's medium (IMDM) (Flow Laboratories), 
supplemented with 10% heat inactivated fetal calf serum (FCS) (HyClone, 
Logan, UT), 50 IU/ml penicillin, 50 μg/ml streptomycin (both Flow 
Laboratories) and 10% dimethylsulfoxide (DMSO). Just prior to the experi­
ments, cells were thawed in a 37°C waterbath, resulting in a recovery of 
>90%. Freezing and thawing procedures have been described in detail else­
where. 1 6 
Recombinant human growth factors
 R e c o m b i n a n t h u m a n i n t e r l e u b n - 3 (IL-
3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were a 
kind gift of Sandoz BV (Uden, The Netherlands). Recombinant human granu­
locyte colony-stimulating factor (G-CSF) was kindly donated by Behring 
(Marburg, Germany). Final concentrations of 40 ng/ml, 20 ng/ml, and 
5 ng/ml of each, respectively, were used and resulted in plateau stimulation. 
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Pulse and prolonged idUrd labeling Normal bone marrow ceUs ( 104 ceUs/ml) 
were suspended in IMDM supplemented with 20% FCS, 50 IU/ml penicillin, 
and 50 μβ/πιΐ streptomycin The cultures were either unstimulated or stimu­
lated with the combination of IL-3, GM-CSF, and G-CSF. IdUrd (Sigma, St. 
Louis, MO) dilutions were prepared from freshly thawed stock solution 
Based on the experience with FCM, pulse-labeling was performed for 2 hours 
at final concentrations of 5, 10, 20,40, 60, and 80 μΜ IdUrd. Incase of pro­
longed labeling, IdUrd at final concentrations of 0.5, 1, 2, 3, 4, 5, and 10 μΜ 
was added to the suspensions. Cells were labeled for a period of 1, 2, 3, 4, and 
5 days. Labeling was performed at 37°C, in a fully humidified atmosphere 
containing 5% CO2 in air. Subsequently, cells were washed three times with 
glucose-phosphate-buffered saline (G-PBS). The cell pellet was resuspended 
in FCS and used for clonogenic assay and cytocentrifugation. In each experi­
ment, one sample not labeled with IdUrd was identically processed and ser­
ved as negative control. The supernatants of the cell suspensions, incubated 
for 1 to 5 days with 1 μΜ IdUrd, were collected before washing and preserved 
at -20°C to determine the remaining IdUrd content by bioassay. 
Clonogemc assay (CFU-GM)
 c d l s w e r e c u k u r e d m I M D M supplemented 
with 20% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin, and 0.3% 
(w/v) bacto-agar (Difco, Detroit, MI). Cells were stimulated with the com­
bination of IL-3, GM-CSF, and G-CSF. Duplicates were cultured in 35- χ 10-
mm culture dishes (Costar, Cambridge, MA) at 37CC in a fully humidified 
atmosphere containing 5% CO2 in air. To obtain 200 to 400 aggregates per 
dish, 2 to 4 χ 104 cells in a total volume of 0.85 ml were plated. The cultures 
were ended after 5 to 7 days, when aggregates consisted of 20 to 60 cells. 
After counting the clusters (5 to 40 cells) and colonies (>40 cells), the agar 
cultures were dried by cytocentrifugation and used for immunoperoxidase 
staining. 
Cytocentrifugation of cells
 C e U s ш s u s p e n s i o n w e r e s e dimented onto a mi­
croscope slide by cytocentrifugation (Shandon, Pittsburgh, PA). Filter cards 
were moistened with 100 μΐ 5% human serum albumin (HSA) in PBS. Next, 
50 μΐ of a cell suspension with a concentration of 5 χ 1 OVml was added in the 
sample chamber The samples were centrifuged at 500 rpm during 10 minu­
tes. The sedimented cells were assessed for IdUrd incorporation by immuno­
peroxidase staining. 
Cytocentrifugation of agar cultures
 T h e m e t h o d u s e d for c y t o c e n t r i f u g a t i o n 
of agar cultures is a modification of the method described by Baines. ' 7 
Cultures were cut into halves and shaken into G-PBS. Each halfwas lifted onto 
a 7 6- χ 26-mm alcohol-cleaned glass slide and covered with a cellulose acetate 
strip (Sepraphore; Gelman Sciences, Ann Arbor, MI). Next, a piece of filter 
paper (Schleicher & Schuell, Dassel, Germany) was put on top, followed by a 
filter card. The cultures were partially dried during 30 to 60 minutes at room 
temperature. Subsequently, the slides were put into cytochps together with 
the plastic sample chambers. They were centrifuged in a cytospin centrifuge 
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at 1500 rpm for 10 minutes. After removel of the filters, a thin agar layer, in 
which the cells were embedded, remained on the glass slide. 
Detection of incorporated IdUrd by indirect immunoperoxidase staining 
The method used to detect incorporated IdUrd was based on a previously 
published protocol developed for flow cytometry. ' 3 A line was drawn around 
the sedimented cells or dried agar cultures with a Dako Pen (Dakopatts, 
Glostrup, Denmark) to keep the solutions on the slides. After an initial wash 
step in PBS, a 1 mg/mi pepsine (Serva, Heidelberg, Germany) 2 N HCl solu-
tion was applied to make the DNA accessible for the antibodies and to neutra-
lize endogenous peroxidase activity in the cytoplasm. After 3 0 minutes, 0.1 M 
Na2B4.C>7 was added for neutralization. Next, pooled human serum (PHS) 
(20% in PBS) was applied to block aspecific binding sites. Subsequently, a 
specific monoclonal anti-IdUrd antibody produced in our institute (HN-IU; 
dilution 1:10) was added. ' 2 Binding of the anti-IdUrd antibody was visuali-
zed by adding the following antibodies: peroxidase-conjugated rabbit anti-
mouse immunoglobulins (dilution 1:100; Dakopatts), peroxidase-conjuga-
ted goat antirabbit immunoglobulins (dilution 1:250; ICN Biomedicals, 
Costa Mesa, CA), and peroxidase-conjugated rabbit antigoat immunoglobu-
lins (dilution 1:2 5 0 ; ICN Biomedicals) Slides were washed in PBS in between 
each step. The incorporated, labeled IdUrd was visualized with 0.5 mg/ml 
3,3-diaminobenzidin tetrahydrochloride (DAB) (Sigma) and 0.01 5% H2O2 
at pH 7.8 in PBS. After 10 to 12 minutes incubation at 37°C, the slides were 
washed by running them under tap water for 10 minutes, counterstained 
with hematoxylin solution (Merck, Darmstadt, Germany), and fixated with 
alcohol (70, 80, 90, 96, 100, 100, and 100%) and xylene substitute (Shan-
don) . The slides were covered with Mahnol (Schmid, Köngen, Germany) and 
a 24- χ 5 0-mm glass slide for microscopical examination In each experiment, 
a sample not labeled with IdUrd was identically treated and served as negative 
control. 
scoring д
 c e
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 w a s c o n s i ¿ e r e c | IdUrd"1" when its nucleus contained one or 
more brown-black spots or when the nucleus was colored totally brown-
black Aggregates were considered positive, when >50% of the cells in the 
aggregate were positive for IdUrd. Per experiment, 100 to 200 aggregates 
were analyzed. The percentage of positive aggregates was calculated as: 
no. of IdUrd4" aggregates 
no. of IdUrd"1" aggregates + no. of IdUrd" aggregates 
All experiments were analyzed by one individual. 
Thymidine suicide
 д m o d lf l c a t i o n o f t h e m e t h o d of Becker et al. was used for 
thymidine suicide.3 Cells ( 104/ml) were suspended in IMDM supplemented 
with 20% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin, and half of the 
specimen was exposed for 30 minutes to 3H-TdR (25 Ci/mM and 1 mCi/ml) 
at 37°C. The final concentration was 100 цСі/тІ. Subsequently, cells were 
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washed three times with cold G-PBS, containing 100 μg cold thymidine per 
ml. The remaining cell pellet was resuspended in FCS and used for clonogenic 
assay. The other half of the cells was not exposed to 3H-TdR; the cells were 
incubated, washed, and plated in agar identically to the suicided specimen 
and served as controls. The percentage of progenitor cells in S-phase was cal­
culated as. 
no of control aggregates - no. of aggregates after
 3H-TdR exposure 
no. of control aggregates 
0 l
~ The human (mycoplasma-free) leukemic cell line Molt-4 was cultur-
edmRPMI 1640 (Flow Laboratories) supplemented with 10% FCS, 50IU/ml 
penicillin, 50 μg/ml streptomycin and 2 mM L-glutamin (Flow Laboratories) 
in a 5% CC>2-humidified atmosphere at 37°C. The cell density was 0.25 to 
1.0 χ 106 cells/ml. Exponentially growing cells were either exposed to IdUrd 
(40 μΜ), 3H-TdR (100 μ α / m l ) , or medium (control) for 30 min at 37°C. 
After subsequent washing with cold G-PBS (containing 100 μg cold thymidi­
ne per ml), part of the cells was used for counterflow centrifugation. Of the 
remaining noncentnfuged cells, one fraction was used for clonogenic assay 
and another was fixed in cold 75% ethanol for DNA analysis. ' 3 
Molt-4 clonogenic assay
 c d l s w e r e c u k u r e d i n R p M I j 6 4 0 supplemented 
with 10% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin, 2 mM L-gluta­
min, and 0.3% (w/v) bacto-agar. Per experiment eight 35- χ 10-mm dishes 
containing 500 cells in 0.85 ml medium were cultured at 37°C in a fully hu­
midified atmosphere containing 5% CO2· After 4 days, the aggregates (eight 
to 32 cells) were counted. Agar cultures of IdUrd labeled cells were dried by 
cytocentrifugation and used for immunoperoxidase staining. 
Counterflow centrifugation of Molt-4 cells
 C o u n t e r f l o w centrifugation (CC) 
was performed with a multichamber rotor (Curarne 3000; Dijkstra Ver-
eemgde, Amsterdam, The Netherlands) to enrich Molt-4 cells in Gj and S-
phase. ' 8 The elutnation profiles proved to be identical for the different cham­
bers.1 8 One chamber contained control cells, a second chamber thymi-
dine-labeled, and a third IdUrd-labeled cells. Cells collected at a decreasing 
rotor speed showed a progressively larger cell volume and represented dis­
tinct populations of cells in transition from G1 phase, through S-phase to G2M 
phase. On the basis of DNA histograms, collected fractions were combined to 
obtain four different fractions representing an 'early' and 'late' Gi fraction 
and an 'early' and 'mid' S-phase fraction Of each fraction, cells were used for 
DNA analysis and clonogenic assay. 
Bivariate f l o w c y t o m e t r i c IdUrd/DNA analysis in suspension тл;
 а г
;
а г Р
 ς ί 3 ί η ί η σ 
for IdUrd incorporation and DNA content was performed using the simulta­
neous proteolytic enzyme digestion and acid denaturation technique. 1 3 · 1 9 
The anti-IdUrd HN-IU MoAb and a fluorescein isothiocyanate (FITC)-conju­
gated IgG goat antimouse second-step antibody (GAM-FITC) (American 
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Qualex International, La Mirada, CA) were used for detection of IdUrd. Pro-
pidium iodide (PI) was used for DNA staining. IdUrd staining of the cell sus­
pensions was always performed in duplicate and all incubation steps were 
executed in the dark. Non-IdUrd-labeled low-density blood cells served as 
negative controls. Samples were analyzed on a Coulter Epics Elite (Coulter, 
Hialeah, FL) flow cytometer equipped with a 40 mW Argon ion laser running 
at 15 mW. A high-pass filter of 610 nm for red fluorescence (PI), a band-pass 
filter 5 2 5 / 3 0 for green fluorescence (FITC), and a dichroic mirror of 5 5 0 nm 
were used. A minimum of 20,000 cells were analyzed in duplicate. The fluor­
escence signals were recorded on a linear scale in list mode. The labeling 
index was defined as the percentage of IdUrd-labeled cells 
Bioassay for the detect ion of residual IdUrd after pro longed label ing v r o r m a l 
bone marrow cells were suspended in IMDM containing 20% FCS and the 
combination of IL-3, GM-CSF, and G-CSF. The cells were cultured in an incu­
bator for 3 days to attain a high proportion of proliferating cells. After wash­
ing with G-PBS, the pelleted stimulated cells were suspended in thawed 
supernatants and cultured in an incubator for another 24 hours The used 
supernatants were collected from the cell suspensions, incubated with 1 μΜ 
IdUrd for a period of 1 to 5 days. As control, cells were also exposed to freshly 
prepared 1 μΜ IdUrd. After incubation, the cells were washed with G-PBS. 
The cell pellet was resuspended in FCS and used for cytocentnfugation and 
clonogenic assay. Subsequently, immunoperoxidase staining was performed 
to determine whether the supernatants contained sufficient IdUrd to label 
cells in S-phase. 
Statistics values were expressed as mean ± 95% confidence interval (CI) of 
the mean. After IdUrd labeling, the binomial distribution was applied to cal­
culate the 95% CI of the mean percentage of progenitors in S-phase. 
Significance of IdUrd concentration level was tested with variance analysis 
(ANOVA with Duncan-Waller test). 2 0 
Results 
D e v e l o p m e n t of the d e t e c t i o n of i n c o r p o r a t e d IdUrd 
Immunoperoxidase staining
 T h e fìm s [ e p w a ¡ . ( h e a d a p t a t k m o f t h e p r o t o c o l 
for IdUrd detection by immunofluorescence developed for FCM. ' 3 In our 
hands, it was difficult and time-consuming to identify aggregates in agar cul-
tures when fluoresence was used; we preferred an immunoperoxidase stai-
ning technique. This allowed evaluation by light microscopy. All aggregates, 
whether positive for IdUrd or not, could easily be visualized after counter-
staining. A sandwich method of three subsequent additions of peroxidase-
conjugated immunoglobulins was chosen. Intensification of the signal with 
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these three peroxidase-conjugated immunoglobulins proved to be superior 
to the signal obtained with only one or two peroxidase-conjugated immu­
noglobulins (data not shown). 
Adaptat ion of the semisol id (agar) culture and culture t ime τ ^ j г л 
usual 2.0 ml, a reduced volume of 0.85 mlper dish was plated. Incorporated 
IdUrd was more easily accessible for antibodies when the thickness of the agar 
culture was reduced. Subsequent mitoses of the clonogenic cell are expected 
to dilute the IdUrd signal, which may result in false-negative colonies. The 
percentage of IdUrd"1" bone marrow colonies after 7 culture days (average 
colony size=64 cells) was the same as determined after 3 days (average cluster 
size=16 cells, data not shown). This indicated that the immunoperoxidase 
staining was at least sensitive enough to detect IdUrd in colonies consisting of 
maximally 64 cells. All cells present in smaller clusters contained at least three 
spots, whereas most, but not always all, cells of the larger colonies contained 
one or a few spots (Fig. 1 ). 
Figure 1 Examples 
of ldUrd+ aggregates. 
a Normal CFU-GM 
cultured after24-
hour labeling with 
1 μΜ IdUrd. 
b Molt-4aggregate 
cultured after pulse 
labeling with 40 μΜ 
IdUrd. 
'1 
* *
ч
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Figure 2 Joxicityof IdUrd pulse-labeling with IL-3.GM-CSF, and 
G-CSF stimulated CFU-GM. Normal bone marrow cells were labeled 
with various concentrations of IdUrd for 2 hours. Subsequently, the 
number of CFU-GM was determined and expressed as a percenta­
ge of the control cultures (incubated without IdUrd). The graphic 
represent the mean percentage (± 95% CI) of three normal bone 
marrows. 
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Toxicity Yke idUrd toxicity was tested on three different normal bone mar­
rows. The cells were cultured for 4 days in the presence of the combination of 
IL-3, GM-CSF, and G-CSF to obtain a high proportion of cycling progenitors. 
IdUrd was added during the last 2 hours of incubation. The number of CFU-
GM was not significantly reduced, even after incubation with 80 μΜ IdUrd 
(Fig. 2). However, the size of the aggregates cultured after incubation with 
8 0 μΜ IdUrd was smaller compared to control cultures. Therefore, 8 0 μΜ was 
considered to be toxic. In addition, peroxidase staining was performed on 
sedimented cells of the suspensions after labeling with the different IdUrd 
concentrations. All samples contained IdUrd+ cells. Part of the cells labeled 
with 80 μΜ were covered with a brown smear. It appeared as if their nuclei 
were no longer intact. This, again, suggested toxicity. 
Signal intensity
 C e U s w e r e p u i s e_labeled for a period of 2 hours. Because of 
an insufficient amount of incorporated IdUrd, a shorter period may under­
estimate the number of clonogenic cells in S-phase, whereas a longer period 
may result in overestimation. Pulse-labeling with 5 μΜ IdUrd resulted in a 
significantly lower percentage of positive aggregates when compared to the 
other tested IdUrd concentrations. The mean (±95% CI) positive percentage 
was 22±20 after pulse labeling with S μΜν5. 42±8, 37±12, and 4S± 12 after 
labeling with 10, 20, and 40 μΜ respectively (Duncan-Waller; η = 3,p<0.05) 
(Fig. 3). The percentages of positive aggregates after labeling with 10, 20, and 
40 μΜ IdUrd were not significantly different. The lower percentage of positi­
ve aggregates found after 80 μΜ labeling suggested toxicity towards colony-
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F i g u r e 3 signal intensity after IdUrd pulse labeling. Normal bone marrow cells from three donors 
were labeled with various concentrations of IdUrd for 2 hours. Subsequently, clonogenic assays 
were performed. Cultures were ended after 6 days and the incorporated IdUrd was detected by 
immunoperoxidase staining. The diagram shows the mean (± 95% CI) percentage of positive and 
negative colonies for each IdUrd concentration. Colonies of which the brown staining was too vague 
to determine whetherthey were positive or negative are represented as undetermined. 
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forming cells that incorporated IdUrd After labeling with 5,10 and 20 μΜ 
IdUrd, the brown staining in a small percentage (<10%) of the aggregates 
was too vague to determine whether they were positive or negative Taking 
both toxicity and signal intensity into account, 40 μΜ was considered to be 
the optimal IdUrd concentration for pulse-labeling 
Sensitivity Molt-4
 c e
j i
s w e r e U Sed to check whether all clonogenic cells in S-
phase were sufficiently pulse-labeled with IdUrd to be detected by ïmmuno-
peroxidase staining If not, an underestimation of the percentage of colony-
forming cells in S-phase may occur In contrast to normal bone marrow cells, 
Molt-4 cells have a high plating efficiency (20 to 50%) Therefore, cell cycle 
analysis of the total cell population can be considered to approximate the 
cycling status of the colony-forming cells The percentage Molt-4 cells in S-
phase was determined by FCM using IdUrd incorporation After pulse labe-
ling, 40 9% of the overall Molt-4 cell population was in S-phase, whereas 
45 6% (41 1 to50 3,mean±95%CI) of the colonies wereIdUrd+ (Table 1) 
Table 1 Comparison of the percentage of clonogenic Molt-4 cells in S-phase determined 
by3H-TdR Suicide and IdUrd pulse-labeling in CC fractions containing different 
percentages of S-phase cells 
CC 
fraction3 
Total 
1 
2 
3 
4 
%S-phase 
cells0 
40 9 
132 
27 8 
45 8 
69 9 
CFU-Moltc 
Control 
1066±76 
146 + 2 0 
31 6±5 6 
65 9 ± 4 2 
925±80 
3H-TdR 
59 8 ± 9 0 
153±32 
26 0 ± 2 6 
26 0 ± 3 4 
11 1 ±32 
Suicide 
index (%)d 
43 9 
283-595 
-4 8 
-40 4 - 30 8 
177 
-82-436 
60 5 
490-720 
88 0 
75 9-1001 
IdUrd* 
CFU-Molt(%)e 
45 6 
41 1-503 
148 
114-190 
30 6 
255-362 
52 2 
460-584 
701 
649-748 
a Fractions (1 to 4) obtained with CC at decreasing rotor spead The total fraction represents 
Molt-4 cells that were not elutriated 
b Percentage of Molt-4 cells in S-phase determined by IdUrd incorporation 
с Mean number (± 95% CI, η = 8 cultures) of Molt-4 colonies / 500 cells 
d Mean percentage (± 95% CI, n=8 cultures) of CFU-Molt-4 in S-phase determined by 
3H-TdR suicide 
β Mean percentage (± 95% CI, η = 8 cultures) of CFU-Moft-4 in S-phase determined by 
IdUrd pulse-labeling 
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T a b l e 2 Comparison of the percentage of CFU-GM in S-phase determined by 3H-TdR suicide and 
IdUrd pulse-labeling in four normal bone marrows 
CFU-GMa 
-22 8 
- 4 8 8 - 3 2 
160 
- 7 9 - 3 9 9 
42 
1 8 - 9 5 
33.3 
27 5-39 8 
Case Culture Suicide IdUrd* 
no conditionb Control 3H-TdR index (%)c CFU-GM (%)d 
1 Unstimulated 154 3 ±20.9 189.5 ±19 4 
Stimulated 409 0 ±34.3 343 7 ±63 7 
Unstimulated 108.7±18.3 107 3 + 5.2 13 8 3 
-20.3-229 4 4 - 1 5 0 
Stimulated 328.7 + 12.7 163 3 ± 19 2 503 56.5 
407-59.6 4 9 3 - 6 3 4 
Unstimulated 985 + 200 96 0 ± 2 8 2 5 10.4 
-206-25.6 6 6 - 1 6 0 
Stimulated 214.0 ± 7 1 2 647 + 150 69B 48.2 
2 9 6 - 1 1 0 0 4 2 1 - 5 4 4 
Fresh 446 5 + 84 9 293 5±31 0 342 203 
8.2-60.2 14.2-28.3 
Unstimulated 176 0 +15.1 164.0 ±36.7 6.8 9.3 
-22.6-36 2 5 6 - 1 5 1 
Stimulated 140.7±7.4 6 3 0 ± 1 1 0 552 36.4 
34.4-76.0 30 4-42.9 
a Mean number of CFU-GM/0 3 χ 105 nucleated cells (± 95% CI, n = 6). 
b Thawed normal bone marrow cells were tested 4 days after liquid culture in the absence 
(unstimulated) or presence 
(stimulated) of the combination of IL-3, GM-CSF, and G-CSF In case 4, freshly obtained 
bone marrow cells were also tested 
с Percentage (± 95% CI, n=6 cultures) of CFU-GM in S-phase determined by 3H-TdR suicide. 
d Percentage (± 95% CI, η = 200 aggregates) of CFU-GM in S-phase determined by IdUrd 
pulse-labeling. 
In addition, Molt-4 cells were elutriated to create cell populations with an 
increasing number of S-phase cells. This allowed evaluation of the accuracy 
of IdUrd pulse-labeling under different conditions. The percentage of S-
phase cells increased from 13.2% in fraction 1 to 69.9% in fraction 4 (Table 
1). The percentage of IdUrd+ CFU-Molt-4 increased from 14.8% (11.4 -
29.0) m fraction 1 to 70.1% (64.9- 74.8) in fraction 4. The percentage of 
IdUrd"1" colonies corresponded strongly with the percentage S-phase cells. 
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Comparison of 3H-TdR suicide and IdUrd pulse-labeling T J I J - J
 n i l ] c p labeling 
was compared with 3H-TdR suicide, which is considered to be the most relia­
ble suicide technique 4 Unfractionated Molt-4 cells and Molt-4 cell fractions 
containing different quantities of S-phase cells were tested The fractions were 
obtained by counterflow centrifugation. Comparison between the suicide 
index and the percentage of IdUrd"1" CFU-Molt-4 revealed no significant diffe­
rences for the five tested samples (Table 1 ). The wide confidence intervals of 
the suicide technique contrasted with the small confidence intervals obtained 
with IdUrd pulse-labeling. 
In a second set of experiments, normal bone marrow cells were cultu­
red for 4 days in the absence or presence of the combination of IL-3, GM-CSF, 
and G-CSF to generate colony-forming cells with a low and high proliferative 
activity, respectively. In unstimulated thawed bone marrow the percentage of 
CFU-GM in S-phase varied from -23 to 7% when determined with thymidine 
suicide and from 4 to 10% when assessed with IdUrd pulse-labeling (Table 
2). After stimulation with the combination of growth factors, the percentage 
of CFU-GM in S-phase ranged from 16 to 70% (3H-TdR suicide) and 33 to 
56% (IdUrd pulse-labeling). No significant differences were observed 
between the percentages obtained with 3H-TdR suicide and IdUrd labeling. 
The confidence intervals of the suicide index were again much wider than 
those of the IdUrd pulse-labeling. The fresh bone marrow sample showed a 
higher percentage of clonogenic cells in S-phase with both methods, proba­
bly owing to the presence of viable CSF-producing monocytes in this sample 
(Table 2, sample 4). 
Prolonged labeling 
Toxicity of various concentrations of IdUrd during 5-day incubation T U P f r ) Y . 
city was tested on three normal bone marrows. Cells were stimulated with the 
combination of IL-3, GM-CSF, and G-CSF to obtain a high proportion of pro­
liferating cells. It appeared that prolonged labeling with IdUrd concentrations 
of 2 μΜ and higher was toxic for CFU-GM (Fig 4). The curves obtained with 
2, 3,4, and 5 μΜ showed no further decrease in CFU-GM number after 4-and 
5-day exposure. This could indicate that IdUrd concentrations had decreased 
below toxic levels. Therefore, the concentration of IdUrd in time was investi­
gated 
Sensitivity Theoretically, 1 μΜ IdUrd could be too low to label all clonogenic 
cells in S-phase. Therefore, the percentage of positive colonies obtained after 
24-hour labeling with S μΜ (the highest nontoxic concentration) as well as 1 
μΜ and 0.5 μΜ were compared. It appeared that about 75% of the colonies 
were IdUrd"1" at all three concentrations tested (Fig. 5). This demonstrated that 
1 μΜ IdUrd was sufficient to label all cycling cells during a period of at least 24 
hours. 
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- θ - 0.5 μΜ 
- · - 1.0 μΜ 
- * - 2.0 μΜ 
- Φ — 3.0 μΜ 
- θ - 4.0 μΜ 
- • - 5.0 μΜ 
-Α— ΙΟ.ΟμΜ 
1 2 3 4 5 
EXPOSURE PERIOD (DAYS) 
Figure 4 Toxicity of prolonged IdUrd labeling toward CFU-GM. Normal bone marrow cells were 
labeled with various concentrations of IdUrd for up to 5 days. Subsequently, the number of CFU-GM 
was determined and expressed as a percentage of the control cultures (100%) (incubated without 
IdUrd). The graphic representthe mean percentage (±95% CI) of three normal bone marrows. 
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Figure 5 Signal intensity after prolonged IdUrd labeling. 
Normal bone marrow cells from three donors were labeled 
with various concentrations of IdUrd for 24 hours. 
Subsequently, clonogenic assays were performed. Cultures 
were ended after 6 days and the incorporated IdUrd was 
detected by immunoperoxidase staining. The diagram shows 
the mean (±95% CI) percentage of ldUrd+ colonies for each 
concentration of IdUrd. 
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DAYS OF INCUBATION 
Figure 6 IdUrd concentration in time. IL-3,GM-CSF, and 
G-CSF-stimulated normal bone marrow cells were incubated 
with supernatants collected after incubation of cell 
suspensions with 1 μΜ IdUrd for a period of 1 to 5 days. 
As control, cells were also incubated with a freshly prepared 
1 μΜ IdUrd suspension (=dayO). After 24 hours, clonogenic 
assays were performed. Cultures were ended after 6 days and 
IdUrd was detected by immunoperoxidase staining. The mean 
(±95% CI) percentage of ldUrd+ colonies reflects the residual 
amount of IdUrd which could be incorporated. 
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IdUrd concentration m time
 T h e ЮХ1СПу s t u d y i n d icated that 1 μΜ IdUrd was 
the highest concentration that could be safely used for prolonged labeling 
IdUrd can be inactivated, especially in media containing FCS not inactivated 
by heat (data not shown). The media used in this study contained heat-inacti-
vated FCS. Since 1 μΜ or less IdUrd was below the detection limit of high-per­
formance liquid chromatography (HPLC), a bioassay was performed. It ap­
peared that IdUrd sufficient to label colony-forming cells for up to S days was 
present in the supernatants. The percentages of positive colonies were the 
same as obtained after exposure to a freshly prepared 1 μΜ solution (Fig. 6). 
However, the intensity of the signal in the colonies, cultured after incubation 
with the supernatant from day 4 and day 5, was reduced 
Discussion 
Suicide techniques are available to study the kinetics of colony-forming cells 
in vitro. The fractional reduction in cloning efficiency after exposure to 3 H-
TdR, HU or Ara-C may not always estimate the percentage of S-phase cells 
correctly.2·4·5 Calculation of the suicide index is based on the subtraction and 
division of colony numbers. This is a major disadvantage of all suicide techni­
ques. The confidence intervals of colony-forming assays are substantial. A 
95% CI o f - 2 0 % is not uncommon. 3 · 2 ' Statistically, this has a great impact on 
the accuracy of the suicide index Calculation of the 95% CI of the suicide 
index of some publications revealed a variation up to 3 0%.3 ·2 ' 
Nonradioactive IdUrd appears to be an attractive alternative for deter­
mining the proportion of colony-forming cells in S-phase. In contrast to the 
suicide techniques, the percentage of IdUrd"1" colonies per culture dish is inde­
pendent of the variation in colony numbers. In stead, the exactness of the esti­
mated percentage S-phase cells depends on the total number of analyzed colo­
nies. 2 0 
After adaptation of a protocol developed for immunological detection 
of IdUrd by FCM, IdUrd"1" colonies could easily be detected in agar cultures 
(Fig.l). The lmmunoperoxidase staining technique was sensitive enough to 
detect IdUrd in colonies consisting of maximally 64 cells. 
Toxicity and sensitivity experiments indicated that a 2-hour exposure 
to 40 μΜ IdUrd was optimal for pulse-labeling Underestimation of the per­
centage S-phase cells due to insufficient incorporated IdUrd was excluded by 
extensive studies with Molt-4 cells (Table 1 ). Molt-4 cells and normal bone 
marrow cells with varying percentages of cells in S-phase were used to com­
pare IdUrd pulse-labeling with 3H-TdR suicide. The mean percentage of S-
phase cells determined with IdUrd labeling was not significantly different 
from the percentage obtained with 3H-TdR suicide (Tables 1 and 2). Due to 
the inevitable variation in colony numbers, the extent of the 95% CI of the sui­
cide index was substantial. Based on the evaluation of only 200 aggregates, a 
much smaller confidence interval was calculated in case of IdUrd pulse-labe­
ling. Thus, IdUrd pulse-labeling appeared to be more accurate than 3H-TdR 
suicide. A negative suicide index, which means higher colony numbers in the 
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3H-TdR exposed fraction, was observed in two samples. Both contained a low 
percentage of S-phase cells (4 2% and 14.8%, respectively when determined 
with IdUrd pulse-labeling) The relatively small number of 3H-TdR killed 
cells fell probably within the variation of the colony-forming assays. Other 
authors made identical observations.3·2 ' It again shows a limitation of suicide 
techniques. 
Toxicity and inactivation of IdUrd and sensitivity of the IdUrd detec­
tion were evaluated to determine the optimal concentration for prolonged 
labeling. It appeared feasible to determine the proportion of cycling clonoge-
nic cells for a period of at least 5 days during which a concentration of 1 μΜ 
IdUrd was used to label the cells Thus, prolonged IdUrd labeling provides the 
unique opportunity to determine the proliferating fraction of progenitor 
cells. With the traditional techniques, only the fraction of S-phase cells can be 
determined. 
During DNA repair, both 3H-TdR and IdUrd will be incorporated into 
non-S-phase cells. In theory, this could result in an overestimation of cells in 
S-phase. However, the number of repaired sites is relatively small compared 
to the doubling of DNA that occurs during S-phase. This suggests only a 
minor or even no detectable effect of DNA repair on the estimation of cells in 
S-phase. In some leukemic samples, we observed that even during 3-day labe­
ling with 1 μΜ IdUrd, < 5 % of the leukemic clonogenic cells were IdUrd"1" 
(data not shown). This additionally supports the limited influence of DNA 
repair on the estimation of S-phase cells 
Prolonged and pulse-labeling with IdUrd can be applied to study the 
proliferative behavior of progenitors under physiological and pathological 
conditions. For example, the effects of growth factors on the in vitro prolifera­
tion of normal and leukemic colony-forming cells can be analyzed. 
Furthermore, cycling data can be correlated to the cytotoxicity of chemothe-
rapeutic drugs. IdUrd can safely be administered to humans. " • ' 2 Kinetic ana­
lysis of in vivo labeled progenitors seems feasible, and the first clinical data are 
currently collected in our institute. 
The present study shows that the percentage of colony-forming cells 
in S-phase can be determined more accurately with IdUrd pulse-labeling than 
with suicide techniques. In addition, prolonged IdUrd labeling makes it pos­
sible to study the proliferating fraction of progenitor cells for at least 5 days. 
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Chapter 5 
Hematopoietic growth factors 
increase the fraction of cycling 
leukemic clonogenic cells and 
reduce the kinetic resistance to 
cytosine arabinoside in vitro 
Netty van der Lely, Reinier Raijmakers, 
Jan Boezeman, Theo de Witte 
Submitted 
Summary 
A recently developed m vitro 3-day ïododeoxyuridine (IdUrd) labeling techni-
que was used to investigate whether growth factors may influence the kinetics 
of leukemic clonogemc cells (CFU-L) and thus may alter the sensitivity to the 
cell cycle-specific drug cytosine arabinoside (Ara-C). In addition, results 
were compared with the effects on normal progenitors (CFU-GM). Liquid 
cultures were performed in the absence and presence of preselected combina-
tions of interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). The 
median percentage of cycling CFU-L increased significantly (p = 0.009) from 
8.5% without growth factors to 87.5% with growth factors in five non-spon-
taneously growing leukemias. The Ara-C sensitivity increased median 63-
fold (range 14-217). The relative percentage of surviving IdUrd+ progenitors 
decreased with increasing concentrations of Ara-C. This indicated that Ara-C 
was preferentially cytotoxic to CFU-L going through S-phase. Two spontane-
ously growing leukemias demonstrated a high proportion of CFU-L in S-pha-
se (93% and 99.3%) and were highly Ara-C sensitive regardless whether 
exposed to the combination of IL-3, GM-CSF, and G-CSF or not. Leukemias 
with a comparable proportion of cycling CFU-L were not equally Ara-C sensi-
tive, suggesting that other than cell cycle-related toxicity was operational as 
well. The three tested normal bone marrows showed a more uniform respon-
se pattern. Even in the absence of growth factors, 70 to 80% of normal CFU-
GM were cycling. The percentage of cycling CFU-GM increased to 100% in 
the presence of the combination of IL-3, GM-CSF, and G-CSF and resulted in 
median 4 3-fold (range 1 4-5.3) enhancement of Ara-C toxicity. 
Our data indicate that the increment of proliferating leukemic clo-
nogenic cells by growth factors may contribute to overcome kinetic resistance 
to Ara-C in AML patients, especially in the setting of protocols with conti-
nuous exposure to Ara-C. 
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Introduction 
A small subset of clonogenic cells within the leukemic population is held 
responsible for the maintenance of the leukemic clone.1"4 Antileukemic the-
rapy should focus on the eradication of these leukemic progenitor cells (CFU-
L) with relative sparing of normal bone marrow stem cells. 
The antileukemic drug cytosine arabmoside (Ara-C) interferes with 
DNA synthesis and is cytotoxic to S-phase cells.5 However, a substantial num-
ber of leukemic blasts is non- or very slowly cycling and therefore may be 
resistant to Ara-C.6"10 Apart from metabolic resistance, this kinetic resistance 
is considered to be an important mechanism for Ara-C resistance in acute 
myeloid leukemia (AML). ' ' Theoretically, clinical results may improve by 
circumvention of kinetic resistance through proliferation induction. As effec-
tive stimulators of leukemic blasts, interleukin-3 (IL-3), granulocyte-
macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-
stimulating factor (G-CSF) are candidates for proliferation induction in 
AML.12"17 
We and others demonstrated that in vitro IL- 3, GM-CSF, and G-CSF may 
enhance Ara-C toxicity towards CFU-L.17"25 In specific AML cases, the most 
optimal promotion of clonogenic cell growth and improvement of Ara-C 
toxicity was achieved by exposure to individually selected growth factors. '7 
These observations suggest that growth factors may increase the number of 
CFU-L in S-phase However, little is known about the effect of growth factors 
on the kinetics of leukemic progenitor cells. One in vitro study determined the in-
fluence of GM-CSF on the percentage of clonogenic cells in S-phase in three 
leukemic samples.19 In these cases, GM-CSF increased the S-phase fraction of 
CFU-L from 39.3 to 67% as demonstrated by Ara-C suicide technique. By 
thymidine suicide technique, a significant increase of clonogenic leukemic 
cells in S phase from 33 to 55% was observed in one patient studied before 
and after 18 h of GM-CSF therapy.26 
Previously, we developed an in vitro technique to measure the fraction 
of actively cycling colony-forming cells by prolonged îododeoxyuridine 
(IdUrd) labeling.2 7 The nonradioactive thymidine analog IdUrd is incorpora-
ted into DNA during S-phase and detected by an anti-IdUrd antibody. When a 
colony-forming assay is performed following the IdUrd exposure, incorpo-
rated IdUrd can be visualized by immunoperoxidase staining. Detection of 
IdUrd in the cells of individual colonies indicates that these colonies origina-
ted from colony-forming cells which passed the S-phase during the labeling 
period. 
In the present study, this new IdUrd technique was used to investigate 
the effects of IL-3, GM-CSF, and G-CSF on the kinetics of CFU-L. Since kinetic 
studies indicate that the median total cell cycle duration is about 70 hours for 
AML blasts,10 a 3-day continuous IdUrd labeling period was chosen. Based 
upon our previous results, ' 7 specific AML cases were tested in the absence and 
presence of individually adapted growth factors shown to result in optimal 
clonogenic cell growth. For comparison, the influence of IL-3, GM-CSF, and 
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G-CSF on normal CFU-GM was also evaluated. Finally, the Ara-C sensitivity of 
CFU-L and CFU-GM was determined and related to the kinetic responses. 
Our data indicate that individually selected colony-stimulating fac­
tors increase the number of cycling CFU-L and reduce the kinetic resistance 
to Ara-C. 
Materials and Methods 
Patients в
о п е
 marrow samples from seven previously untreated AML 
patients were tested. The diagnosis according to the French-American-British 
(FAB) classification was M2 (n = 4) and M4 (n = 3) (Table l ) . 2 8 The bone 
marrow samples contained median 6 1 % blasts (range 35-94). Normal bone 
marrow was obtained from three healthy bone marrow donors. Informed 
consent was given in all cases. 
Bone marrow preparation, cryopreservation, thawing
 N o r m a i a n ¿ leukemic 
bone marrow cells were collected in sterile buffered acid-citrate dextrose (pH 
= 7.0) The normal and leukemic samples were enriched for clonogenic cells 
by flotation centnfugation or centnfugation on a Ficoll (1.085 g/ml) density 
gradient (Sigma, St Louis, Missouri) respectively.29 Normal bone marrow 
cells with a density of < 1.067 g/ml and leukemic interphase cells were cryo-
preserved in liquid nitrogen using a temperature-controlled freezer (Kryo 10; 
Planer Biomed, Sunbury, Middlesex, UK). Vials contained 5-20 χ IO6 cells 
suspended in Iscove's medium (Flow Laboratories, Irvine, Scotland), supple­
mented with 10% heat-inactivated fetal calf serum (FCS) (HyClone, Logan, 
Utah), 50 IU/ml penicillin, 50 μg/ml streptomycin (both Flow Laborato­
ries) and 10% dimethylsulfoxide (DMSO). Just prior to the experiments, cells 
were thawed in a 37°C waterbath, resulting in a recovery of >90%. Freezing 
and thawing procedures have been described in detail elsewhere.30 
Human recombinant growth factors
 H u m a n r e c o m b l n a n t I L _ 3 a n d QM-CSF 
were kindly donated by Sandoz BV (Uden, The Netherlands). Human recom­
binant G-CSF was a generous gift from Behring (Marburg, Germany). The 
final concentrations for plateau stimulation in both liquid and semisolid cul­
tures were 40 ng/ml, 20 ng/ml, and 5 ng/ml respectively 
Liquid cultures with Ara-C and idUrd
 T h a w e d i e u k e m i c and normal cells 
(1 OVml) were cultured in liquid in the absence and presence of preselected 
growth factors for a period of 5 days. The suspensions consisted of Iscove's 
medium supplemented with 20% FCS, 50 IU/ml penicillin, and 50 μg/ml 
streptomycin. Previous experiments showed a median survival of the clo­
nogenic cells of more than 100% under these conditions. ' 8 The choice of the 
added factor(s) was based on previous experiments in which the responsive­
ness to IL-3, GM-CSF, and G-CSF, both alone and in combination, was esta­
blished in liquid cultures. ' 7 Growth factor(s) resulting in the highest number 
of CFU-L were selected for the leukemic samples. The combination of IL-3, 
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GM-CSF, and G-CSF yielded the best results in normal bone marrow samples 
Cells were allowed to recover from thawing and to adjust to the culture condi­
tions for 2 days. During the next 3 days of incubation, 1 μΜ of IdUrd (Sigma) 
was added to duplicate cultures. These samples were used to determine the 
number of cycling clonogenic cells and served as the 100% control growth. 
Previous experiments showed that 1 μΜ of IdUrd was not toxic for myeloid 
progenitor cells.27 To parallel liquid cultures, various Ara-C concentrations 
(Upjohn, Kalamazoo, Michigan) were added during the last 3 incubation 
days. The final concentrations varied from 10"'° to 1 0 s M Ara-C. Dilutions 
were prepared from freshly thawed Ara-C stock solutions. The drug was check­
ed for concentration, purity, and stability by high-performance liquid chro­
matography.3 ' Four leukemic samples were also exposed to Ara-C in the pre­
sence of 1 μΜ IdUrd to determine the percentage of cycling CFU-L at certain 
Ara-C concentrations. After culture in an incubator (3 7°C, 5% CO2 in air and 
fully humidified atmosphere), the cells were washed with glucose-phosphate-
buffered saline (G-PBS) and used for clonogenic assay. 
Clonogenic assay (CFU-GM/L)
 C e U s w e r e c u l t u r e d m I s c o v e ' s m e d i u m sup­
plemented with 20% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin, and 
0 3% (w/v) bacto-agar (Difco, Detroit, Michigan). Cells were stimulated 
with the combination of IL-3, GM-CSF, and G-CSF. Duplicates were cultured 
in 3 5- χ 10-mm culture dishes (Costar, Cambridge, Massachusetts) at 3 7CC in 
a fully humidified atmosphere containing 5% CO2 in air. Per dish, a total 
volume of 0.85 ml was plated. The cultures were evaluated after 5 to 7 days, 
when aggregates consisted of 20-60 cells. This enabled a reliable detection of 
IdUrd in the aggregates.27 The CFU-L aggregates consisted of immature cells. 
The CFU-GM aggregates usually contained mature granulocytes and/or 
macrophages. After enumerating the clusters (5-40 cells) and colonies (>40 
cells), the agar cultures were dried by cytocentrifugation and used for ìmmu-
noperoxidase staining. 
Cytocentrifugation of agar cultures
 T h e m e t h o d u s e d B a m o d l f k a t l o n o f t h e 
method described by Baines.32 Cultures were cut into halves and shaken into 
G-PBS. Each halfwas lifted onto a 76- χ 26-mm glass slide and covered with a 
cellulose acetate strip (Sepraphore, Gelman Sciences, Ann Arbor, Michigan). 
Next, a piece of filter paper (Schleicher & Schuell, Dassel, Germany) was put 
on top, followed by a filter card. The slides were centrifuged in a cytospin cen­
trifuge at 1500 rpm for 10 minutes (Shandon, Pittsburgh, Pennsylvania). 
After removal of the filters, a thin agar layer, in which the cells were embed­
ded, remained on the glass slide. 
Detection of incorporated IdUrd by indirect immunoperoxidase staining 
The method used to detect incorporated IdUrd was based on a previously 
published protocol developed for flow cytometry and has been described in 
detail elsewhere.2 7·3 3 A 1 mg/mi pepsine (Serva, Heidelberg, Germany) 2 N 
HCl solution was applied on the dried agar cultures. After 30 minutes, 0.1 M 
Na2B4.C>7 was added for neutralization. Next, pooled human serum (PHS) 
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(20% in PBS) was applied to block aspecific binding sites. Subsequendy, a 
specific monoclonal anti-IdUrd antibody produced in our institute (HN-IU, 
dilution 1:10) was added.34 Binding of the anti-IdUrd antibody was detected 
by subsequent addition of peroxidase-conjugated rabbit antimouse immu-
noglobulins (dilution 1:100, Dakopatts, Glostrup, Denmark), peroxidase-
conjugated goat antirabbit immunoglobulins (dilution 1:250, ICN 
Biomedicals, Costa Mesa, California), and peroxidase-conjugated rabbit anti-
goat immunoglobulins (dilution 1 250, ICN Biomedicals). The incorpora-
ted, labeled IdUrd was visualized with 0.5 mg/ml 3,3-diaminobenzidin te-
trahydrochloride (DAB) (Sigma), 0.01 5% H 2 0 2 at pH 7.8 in PBS. The slides 
were counterstained with hematoxylin solution (Merck, Darmstadt, 
Germany), and fixated with alcohol and xylene substitute (Shandon). In each 
experiment, an IdUrd"1" and an IdUrd" sample were identically treated and ser-
ved as controls. 
IdUrd scoring
 A g g r e g a t e s w e r e considered IdUrd+ when >50% of the cells in 
the aggregate were positive for IdUrd. A cell was considered IdUrd+ when its 
nucleus contained one or more brown-black spots or when the nucleus was 
totally brown-black colored. Per experiment, 100 to 250 aggregates were 
analyzed. The percentage of positive aggregates was calculated as: 
no. of IdUrd"1" aggregates 
no. of IdUrd"1" aggregates + no. of IdUrd" aggregates 
All experiments were analyzed by one single individual. 
Curve f,tt,ng and statistics
 T Q fì[
 ± е д г а . с ¿Qse r e s p o n s e c u r v e S p t h e foUo. 
wing formula was used: 
In this formula α stands for the maximal plating efficiency (100%, measured 
when the cells are incubated without Ara-C) and b for the Ara-C concentration 
at which inhibition is 70%; с represents the slope of the curve. The data were 
fitted according to the Gauss-Newton regression procedure with the use of 
the least squares criteria.35 The Ara-C concentrations resulting in 50% inhibi­
tion of clonogenicity (ID50) were calculated from these curves. 
Values were expressed as mean ± 95% confidence interval (CI), as mean ± 
standard error of the mean (SEM) or as median with range. The binomial dis­
tribution was applied to calculate the 95% CI of the mean percentage of 
IdUrd"1" progenitor cells.36 Group data were compared by Mann-Whitney 
test. 
6 8 I C H A P T E R F I V E 
Relation between factor responsiveness, percentage of cycling clonogenic cells and Ara-C toxicity 
Ara-C 
Patient FAB 
type* 
Spontaneously 
growing* 
Added 
factor' 
Control 
growth11 
IdUrd*' '°50 
x l O ' M ' 
262 
191 
>1000 
4Б 
97 5 
39 
15 
26 
70 4 
06 
37 8 
06 
01 
01 
149 
28 
23 
17 
Sensitivity 
Increase 
1 4 8 x 
>217 4 x 
25 Ox 
06x 
1173X 
63 Ox 
Ю х 
53x 
14x 
M2 
M2 
M2 
M2 
M4 
M4 
M4 
Normal 
BM 
Normal 
BM 
Normal 
BM 
No factor 
GM-CSF 
No factor 
ІІ-Э+ 
GM-CSF+ 
G-CSF 
No factor 
11-3+ 
GM-CSF+ 
G-CSF 
7900 
21200 
2800 
No factor 
GM-CSF 
No factor 
11-3+ 
GM-CSF+ 
G-CSF 
No factor 
GM-CSF+ 
G-CSF 
No factor 
GM-CSF 
No factor 
11-3+ 
GM-CSF+ 
G-CSF 
No factor 
11-3+ 
GM-CSF+ 
G-CSF 
No factor 
11-3+ 
GM-CSF+ 
G-CSF 
110 
1800 
6100 
4600 
5000 
23000 
4300 
16200 
4700 
2800 
1000 
2700 
1900 
4600 
1100 
3600 
73 
4 5 - 1 1 7 
65 5 
5 6 7 - 7 1 7 
25 
1 1 - 5 7 
89 2 
833-914 
37 1 
28 5 - 46 7 
87 5 
82 2 - 91 4 
93 0 
880 961 
97 4 
93 6 - 99 0 
85 
52-138 
68 0 
583-763 
22 9 
173 296 
885 
83 3 - 92 2 
95 3 
909 976 
993 
959-999 
713 
651-768 
100 0 
967-1000 
731 
641-806 
1000 
97 3-100 0 
817 
754-866 
1000 
979-1000 
52 
12 43x 
a French-Amencan-Bntish classificationa 
b Defined as the formation of aggregates in semisolid culture in the absence of exogenously added growth factors 
с Growth factor(s) added to the liquid culture 
d CFU-L/CFU-GM number per 2 χ 105 'input' cells, assessed in duplicate after 5-day liquid culture in the absence of Ara-C 
• Percentage (± 95% CI) of cycling CFU-L/CFU-GM determined by 3-day IdUrd labeling 
/ Ara-C concentration that inhibited 50% of the CFU-L/CFU-GM growth The values were calculated from survival curves 
constructed after 3-day exposure to various concentrations of Ara-C 
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Results 
Non-spontaneously growing leukemias 
Of the seven tested leukemias, five did not form aggregates when cultured in 
semisolid medium in the absence of exogenously added growth factors 
(patients 1, 2, 3, 5, and 6, Table 1 ). These leukemias were considered to be 
non-spontaneously growing. After incubation with IdUrd for 3 days in the 
absence of growth factors, a median number of 8.5% (range 2.5 to 37.1) 
colony-forming cells were IdUrd+ (Table 1). Exposure to Ara-C for 3 days 
resulted in ID50 values ranging from >10" 5 to 3.8 χ ΙΟ"7 M Ara-C. In the pre­
sence of individually selected stimulating factors, the fraction of IdUrd"1" 
aggregates increased significantly (p = 0.009) from median 8.5 to 87.5% 
(range 65.5 to 89.2, Table 1). The ID50 values decreased significantly (p = 
0.009) and ranged from 1.9 χ 10"7 to 6 χ ΙΟ"9 M Ara-C. Compared to the non-
stimulated samples, Ara-C toxicity increased median 63-fold (range 14.8 to 
217) in the presence of growth factors. 
Spontaneously growing leukemias 
Two of the seven tested leukemias formed aggregates when cultured in semi­
solid medium in the absence of exogenously added growth factors (patients 4 
and 7, Table 1). Both in the absence and presence of growth factors, a high 
proportion (93% and 99.3%) of the colony-forming cells of these spontane­
ously growing leukemias were cycling. Either with or without colony-stimu­
lating factors, the ID50 values varied from 2.6 χ 10"8 to 1 χ 10"9 M Ara-C after 
3 -day exposure. No additional increase m Ara-C sensitivity was observed after 
incubation with growth factors. 
Normal bone marrow 
The normal bone marrow samples did not form aggregates in semisolid 
medium when cultured in the absence of exogenously added growth factors. 
Three-day IdUrd labeling during liquid culture in the absence of added 
growth factors resulted in median 73.1% (range 7 1.3 to 81.7 ) posi ti ve colo­
ny-forming cells (Table 1). The ID50 values calculated after 3-day Ara-C 
exposure varied from 2.3 to 14 9 χ 10"8 M Ara-C. In the presence of growth 
factors, 100% of the CFU-GM were IdUrd+ (p = 0.05, when compared to 
incubation without growth factors). The corresponding ID50 values ranged 
from 1.2 to 2.8 χ 10"8 M Ara-C and were not significantly different from the 
values obtained without stimulation (Table 1, ρ = 0.12). 
7 0 I C H A P T E R F I V E 
U n d i s t u r b e d A r a - C t o x i c i t y in t h e p r e s e n c e of I d U r d 
Ara-C and IdUrd are both incorporated into DNA during S-phase and may 
interfere with each other. Blasts of two patients were incubated with Ara-C 
and the combination of Ara-C and 1 μΜ IdUrd to test the influence of IdUrd 
on the Ara-C cytotoxicity. Experiments were conducted in the absence and 
presence of stimulating growth factors. The toxicity curves showed that 1 μΜ 
of IdUrd did not influence the cytotoxicity of Ara-C, since curves with and 
without IdUrd were overlapping in both experiments (Fig. 1 ). 
P r e f e r e n t i a l A r a - C t o x i c i t y t o w a r d s S - p h a s e CFU-L 
In four patients the S-phase dependent kill of Ara-C was further evaluated. 
Blasts were incubated with various concentrations of Ara-C and 1 μΜ IdUrd. 
Cytospin preparations were made to determine the number of IdUrd"1" proge­
nitors after exposure to certain Ara-C concentrations. Samples were tested in 
the presence of preselected growth factors. Increasing concentrations of Ara-
C resulted in a higher kill of CFU-L. The relative percentage of IdUrd+ proge­
nitors decreased with increasing concentrations of Ara-C, indicating that 
IdUrd"1" CFU-L were preferentially killed. A representative example (patient 
1) is depicted in Figure 2. These experiments allowed construction of Ara-C 
survival curves of both the IdUrd"1" and IdUrd" subpopulations. Subsequently, 
ID50 values could be calculated. In all cases, the IdUrd"1" CFU-L populations 
were more sensitive to Ara-C than the IdUrd" CFU-L populations (Table 2). 
T a b l e 2 Дга-С sensitivity for IdUrd* and IdUrd clonogenic leukemic cells 
Ara-C I D 5 n x 1 0 - 8 M a 
Patient 
no 
1 
2 
5 
Added 
factor6 
GM-CSF 
IL-3+ 
GM-CSF+ 
G-CSF 
GM-CSF+ 
G-CSF 
Overall IdUrd* IdUrd" 
191 
4.6 
0.6 
72 
3.5 
0.3 
140 
>10 
0.9 
GM-CSF 0.6 04 >10 
a Ara-C concentration that inhibited 50% of the CFU-L growth. The values were calculated from sur­
vival curves constructed after3-day exposure to various concentrations of Ara-C 
b Growth factor(s) added to the liquid culture. 
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Figure 1 д
га
-С dose survival curves of 
patient 1 (A) and 5 (B) demonstrating the 
undisturbed Ara-C toxicity in the presen­
ce of IdUrd. In the absence and presence 
of the indicated growth factors, blasts 
were exposed to various concentrations 
of Ara-C in the absence and presence of 
1 μΜ IdUrd. After3-day Ara-C exposure, 
the number of surviving CFU-Lwas 
determined by clonogenic assay 
stimulated with the combination of IL-3, 
GM-CSF, and G-CSF. The CFU-Lsurvival 
was expressed asa percentage of control 
cultures. 
120-p percent survival 
100 
60 
20 
• no factor 
О no factor+ldllrd 
• GM+G-CSF 
Δ GM+G-CSF+ldUrd 
10 -10 10 10"" 10"' 10 
Ara-C concentration [M] 
6 
120-p percent survival 
Ara-C concentration [M] 
Figure 2 Дга-C dose survival curve 
of patient 1 constructed after3-day 
exposure to various concentrations of 
Ara-C in the presence of both GM-CSF 
and IdUrd. The number of surviving CFU-L 
was determined by clonogenic assay 
stimulated with the combination of IL-3, 
GM-CSF, and G-CSF and expressed asa 
percentage of control cultures. Each bar 
represents the relative distribution of 
IdUrdt and IdUrd- aggregates at a 
specific Ara-C concentration. The control 
was not exposed to Ara-C, but otherwise 
equallytreated. 
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Discussion 
Augmentation of the cytotoxicity of cycle-specific drugs through recruitment 
of quiescent leukemic clonogenic cells by growth factors has been studied in 
vitro. ' 7-25.37,38 Most studies have been performed with Ara-C in combination 
with GM-CSF and IL-3, although occasionally reports with G-CSF have been 
published. In almost all studies, the kinetic response to growth factors is asses-
sed in the total blast cell population. The percentage of blasts in S-phase is 
determined by propidium iodide or by the incorporation of 3H-thymidine 
(3H-TdR) or bromodeoxyuridine (BrdU) into blasts. In contrast, Ara-C toxi-
city is mainly tested on leukemic clonogenic cells. Since the total population of 
blasts usually comprises < 1 % clonogenic cells, cell cycle analysis of the entire 
leukemic cell population may not necessarily reflect the kinetics of the leuke-
mic progenitor cells.9· ' 9 · 3 7 This may explain why the relation between stimu-
lation and increase of Ara-C toxicity was not always obvious. In some cases, 
enhanced Ara-C toxicity towards CFU-L was observed without a substantially 
increase in S-phase cells.20 On the other hand, increased percentages of S-
phase cells did not always result in a higher kill by Ara-C.25 · 3 7 
To our knowledge, the present study is the first in which the cycling 
behaviour of leukemic cells are studied at a clonogenic cell level during a 3-
day period. The prolonged IdUrd labeling informs about the CFU-L kinetics 
during the entire Ara-C exposure period. In non-spontaneously growing leu-
kemias, significantly higher percentages of CFU-L passed S-phase in cultures 
supplemented with appropriate growth factors compared to CFU-L cultured 
in the absence of growth factors. This supports the theory that hematopoietic 
factors play a major role in the regulation of CFU-L proliferation. Proliferation 
induction with growth factors always corresponded with an increased Ara-C 
sensitivity in all five tested non-spontaneously growing leukemias. Enhance-
ment of Ara-C toxicity did not occur in the two leukemic cases in which pro-
liferation was not altered by growth factors. Different leukemias with the 
same proportion of cycling CFU-L (for example patient 1 and 5) were not 
always equally Ara-C sensitive. This indicated that other than S-phase depen-
dent mechanisms may contribute to the cytotoxicity of Ara-C for instance dif-
ferences in the level of metabolic resistance. Although not all clonogenic cells 
were actively cycling, increasing dosages of Ara-C eventually led to a 100% 
kill. This suggests a cell cycle independent mechanism of toxicity at higher 
concentrations of Ara-C. Earlier studies indeed reported the additional toxic 
effects of high-dose Ara-C.39 
To investigate the S-phase dependent kill of Ara-C in more detail, the 
distribution of IdUrd+ colonies was determined at different inhibiting con-
centrations of Ara-C (Fig.2, Table 2). Ara-C appeared to be preferentially 
toxic to IdUrd"1" progenitors. This supports the hypothesis that actively prolif-
erating CFU-L are more sensitive to Ara-C than slowly- or non-proliferating 
CFU-L. Since both IdUrd and Ara-C are incorporated into DNA during S-
phase, an interaction between the two substances had to be ruled out. In 
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theory, the chain terminating activity of Ara-C could result in a lower and 
thereby undetectable number of incorporated IdUrd molecules. At the same 
time this would lead to substantial DNA damage and presumably cell death. 
We could demonstrate that Ara-C toxicity was not altered in the presence of 
ΙμΜ IdUrd (Fig. 1). 
In contrast to the leukemic samples, normal CFU-GM were already 
actively cycling in the absence of growth factors (median 73.1% IdUrd+) in 
the experimental design used for this study. This may reflect the real percenta­
ge of spontaneous proliferation in vivo or more likely may have been caused by 
for instance endogenous CSF produced by contaminating T-lymphocytes or 
monocytes. The Ara-C sensitivity of CFU-GM in the presence of IL-3, GM-
CSF, and G-CSF was not significantly different from the stimulated CFU-L in 
this 3-day exposure model. This implies a potential risk for the clinical appli­
cation of growth factors in conjunction with Ara-C. However, the sensitivity 
of CFU-GM does not necessarily reflect the sensitivity of the hematopoietic 
stem cells in vivo It is postulated that the majority of normal hematopoietic 
stem cells are out of cycle in vivo. In vitro and in vivo data thus far suggest that in 
the presence of growth factors the toxicity of Ara-C towards normal progeni­
tors is not higher than the toxicity of Ara-C a l o n e . 2 3 · 4 0 · 4 2 · 4 3 , 4 4 We found that 
10-day Ara-C exposure in the presence of the combination of IL-3, GM-CSF, 
and G-CSF resulted in a preferential kill of the leukemic versus the normal 
clonogenic cells in vitro. ' 8 
In vitro models provide a tool to investigate regulatory mechanisms in 
leukemic and normal hematopoiesis. The accuracy of these models can only 
be proven by in vivo studies. Recently, we adapted a protocol for IdUrd admini­
stration to patients in order to reach a sufficiently high, but not toxic plasma 
level to label CFU-L in vivo. The preliminary data indicate that also in vivo only a 
minority of CFU-L is actively cycling.41 
Several recent studies analyzing the influence of G (M) -CSF during 
remission-induction therapy of AML patients reported conflicting data. Some 
authors observed a higher percentage of patients achieving complete remis­
sion after induction chemotherapy in combination with growth factors.43 
Others found no enhancement of remission rates when growth factors were 
given concomitantly with chemotherapy.4 5 These contrasting data may be 
explained by this report. Leukemic blasts not responding to the administered 
CSF are not expected to benefit from the proliferation inducing properties of 
the growth factor Additional studies need to be performed to establish the 
benificial effects of recruitment by growth factors in the treatment of AML 
patients. 
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Summary 
We describe a novel approach to determine the presence of chromosomal 
aberrations in progenitor cells by in situ hybridization (ISH) on agar cultures. 
Bone marrow cells of three patients suffering from acute myeloid leukemia 
(AML) were selected to develop the method. In all three cases, numerical 
aberrations for chromosome 1 and/or 8 were detected by karyotying and ISH 
using chromosome-specific centromenc-associated DNA probes. These aber-
rations were used as markers in this study. After in vitro culture of the bone 
marrow samples in agar, the cells were pretreated to perform ISH. This ap-
proach retains the cytological architecture of the agar assay, allowing discri-
mination between chromosomal aberrations detected in the clonogenic and 
non-clonogenic cells in culture. With this new technique, the presence of the 
cytogenetic aberration in clonogenic cells can be shown at the interphase 
level. 
Introduction 
Hematopoietic neoplasms are assumed to be clonal diseases originating from 
a single cell ' · 2 Therefore, monodonality can be used to further characterize 
these neoplasms. In the majority of myeloproliferative disorders, progenitors 
can be cultured in vitro. Information about the lineage involvement of these 
neoplasms may increase understanding of their pathogenesis and response to 
treatment. Because the origin of clonogenic cells may be difficult to deter-
mine by morphology alone,3 additional techniques have been developed to 
demonstrate the monoclonal origin of progenitors. The X-chromosome-lin-
ked enzyme glucose-6-phosphate dehydrogenase (G6PD), or restriction 
fragment length polymorphisms (RFLP) of other X-chromosome-linked 
enzymes, can be used as a genetic marker in heterozygous women. ' Karyo-
typing and surface marker expression analysis can also be used 3 · 4 
Except for the latter technique, all methods analyze colonies that are 
individually harvested. Apart from being time-consuming, harvesting may 
lead to sampling error because non-clonogenic cells may be removed in place 
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of clonogenic cells due to colony overlap. Since karyotyping analyzes dividing 
cells, cell populations with a selective growth advantage will be favored.4 
Furthermore, within a colony, sufficient proliferative cells must be available. 
Only relatively large colonies (> 100 cells) could be analyzed, although with 
technical improvements smaller colonies (±50 cells) are being investigated 
now.
4 
Nonradioactive ISH of chromosome-specific, centromeric-associated 
DNA probes to interphase cells has become available, determining the copy 
number of a target chromosome by counting the number of hybridization 
signals.5"8 Although this interphase analysis provides only limited informa­
tion about the karyotype, it enables rapid screening of large numbers of cells. 
Until now, few ISH studies have been published in which bone mar­
row and peripheral blood interphase nuclei from patients suffering from leu­
kemia were analyzed at the total cell level 9" ' 3 Although the detection of struc­
tural aberrations is limited using centromeric DNA probes, double-target 
fluorescent ISH experiments on interphase nuclei have shown that the detec­
tion of structural chormosome aberrations is feasible.14 A two-color ISH 
approach can be used to demonstrate the bcr-obl fusion, which is responsible 
for the appearance of the Philadelphia chromosome, in interphase cells of 
chronic myeloid leukemia (CML) patients. 1 5 · 1 6 Also, marker chromosomes 
can be characterized by using these procedures. 
In the present study, the application of interphase cytogenetics at the 
progenitor cell level is descibed. For this approach, we developed a method to 
perform ISH on cells cultured in agar. Since the cytological architecture of the 
agar assay remains intact, discrimination between chromosomal aberrations 
detected in both clonogenic and non-clonogemc cells can be detected. 
Materials and methods 
Sample selection and preparation
 T h r e e k a r y o p t v p e d A M L bone marrow 
samples with numerical chromosome aberrations were selected: monosomy 
for chromosome 1, trisomy for chromosome 8 and a polyploid karyotype. As 
a control, the samples were hybridized with a chromosome-specific probe for 
which no chromosomal aberration was detected. In addition, normal bone 
marrow cells of a healthy donor served as a control. 
Preparations for ISH were made with freshly obtained bone marrow 
cells. The samples were layered onto Ficoll-Hypaque (specific density 1085 
g/ml) (Pharmacia/LKB, Uppsala, Sweden) and centnfuged at 1200 rpm for 
20 minutes 
Part of the collected low-densitiy cells were washed in phosphate-
buffered saline (PBS), fixed in 70% ethanol (-20°C) and stored at -30°C. 
Shortly before ISH, 5 μΐ of a cell suspension was dropped onto slides coated 
withpoly-L-lysine (molecular weight 150 to 300 kd) (Sigma, St. Louis, MO), 
air-dried and heated at 80°C for 1 hour. 
The remaining low-density cells were cultured in Iscove's medium 
(Flow Laboratories, Irvine, Scotland), supplemented with 20% fetal calf 
serum (FCS), 50 IU/ml penicillin, 50 μg/ml streptomycin (both Flow 
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Laboratories) and 0 3% (w/v) bacto-agar (Difco, Detroit, MI). The cells were 
stimulated with the combination of interleukin-3 (IL-3) (40 ng/ml; Sandoz 
BV, Uden, The Netherlands), granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (20 ng/m; Sandoz BV) and granulocyte colony-stimulating 
factor (G-CSF) (5 ng/ml; Behring, Marburg, Germany). Duplicates were cul­
tured m 35- χ 10-mm culture dishes (Costar, Cambridge, MA) at 37CC m a 
fully humidified atmosphere containing 5% CO2· 1 7 The cells (2xl0 5 ) were 
plated m a minimum volume of 0.85 ml Iscove's medium per dish to make 
them more accessible to the probes. After 7 days, the total number of clusters 
(5 to 40 cells) and the total colony number (>40 cells) was counted. The agar 
cultures were lifted out of the culture dishes and, after division into quarters, 
spun down on poly-L-lysine-coated slides by cytocentnfugation. Subse­
quently, the samples were fixed in 70% ethanol, air-dried and stored at 4°C 
until ISH was performed. 
Tumor cell processing for in situ hybrid,zat,on
 д p r o t e o l y t l c digestion Step 
with pepsin at a concentration of 100 μg/ml in 0.01 M HCl for 20 minutes at 
3 7°C was performed to obtain an optimal recovery of cells and proper remo­
val of cellular protein for improvement of DNA probe and antibody penetra­
tion 6 · 9 Thereafter, the nuclei were postfixed in 4% formaldehyde in PBS for 
20 minutes at 4°C. Subsequently, the slides were washed in PBS and H2O and 
equilibrated in 2x SSC (0.3 M NaCl, 3 0 mM Na-Citrate). pH 7.0, for 5 minutes 
at room temperature. 
DNA probes
 T h e p l a s m i d p r o b e s pUCl .77 and D8Z2 (Oncor, Gaithersburg, 
MD) were used for the detection of target sequences on chromosomes 1 and 
8, respectively. ' 8 · ' 9 The probes were labeled by nick-translation with biotin-
11 -dUTP (Sigma), according to the supplier's instructions 
In s i tu hybr id izat ion
 T h e D N A p r o b e s w g r e h y b n d i z e d t o t h e ( ш т о г . ) с е Ц 
preparations as described before in 60% formamide, 2x SSC and 10% dextran 
sulfate at a probe concentration of 1 ng/μΐ hybridization mixture.9 Ten 
microliters of the hybridization mixture was applied to the slides under a 
coverslip (18x18 mm). Denaturation of the probe and targed DNA was per­
formed simultaneously by heating the slides to 70 °C in a moist chamber for 
2.5 minutes. Hybridization was then performed for 2 to 16 hours at 37°C. 
The coverslips were removed by immersing the slides in 60% formamide, 2x 
SSC, pH 7.0. Thereafter, the slides were washed 3 times for 5 minutes in the 
same buffer at 42°C and subsequently 3 times for 5 minutes in 2x SSC, pH 7.0, 
at42°C. 
immunocytochemistry
 D e tection of hybridized cells was accomplished using 
mouse annbiotin (Dakopatts, Glostrup, Denmark) in PBS and 0.05% Tween 
20 with 0 5% blocking milk (Boehnnger, Mannheim, Germany), followed 
by an incubation with biotin-labeled horse antimouse (Vector, Burlingame, 
CA) Next, a final incubation with the ABC complex (avidin-biotin-labeled 
peroxidase complex) (Vectastain Elite ABC Kit) was performed according to 
the supplier's instructions. All immunocytochemical steps were performed 
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for 30 minutes at 37°C. Finally, the DNA probe was visualized with 0.5 
mg/ml 3,3-diaminobenzidin tetrahydrochlonde (DAB) (Sigma), 0.65% 
imidazole (Merck, Darmstadt, Germany) and 0.015% H2O2 (Merck), pH 
7.8, in PBS for 5 minutes. Slides were rinsed in distilled water and the signal 
was amplified with CUSO4 (0.5% in 0.9% NaCl) for 5 minutes at room tem­
perature, washed with distilled water, counterstained with hematoxylin and 
mounted in Permount (Fisher Scientific, Fair Lawn, NJ). 
Evaluation of ISH results
 U s m g ± е d e s c n b e d I S H p r o c e d u r e , at least 90% of 
the interphase nuclei showed one, two or three distinct ISH signals in all pre­
parations. Evaluation of the preparations and counting of ISH signals were 
done by two trained observers according to criteria as described before.6 , 9 
Minor hybridization signals, which can be recognized by a lower intensity 
and spot area, and overlapping nuclei were not counted. 2 0 In the control cells, 
one ISH signal for a targeted chromosome was found in 5 to 10% of the cells, 
depending on the efficiency of the ISH procedure, or the co-localization of 
two ISH signals. The detection of three ISH signals occurred in less than 1 % of 
the normal cells. 
Of the cells from suspension preparations, 200 nuclei per slide were 
counted. The agar preparations were evaluated by counting 200 single cells in 
agar (representing non-clonogenic cells) and approximately 50 aggregates 
(both colonies and clusters). Since the aggregates represent clonogenic cells, 
all the cells in an aggregate should be the same, and the distribution of ISH sig­
nals would be an indication for the clonality of the aggregates. Therefore, a 
cell count of the distribution of ISH signals in an aggregate was not necessary. 
Moreover, the same criteria for evaluation as described previously could be 
applied.9·2 0 In an aggregate, about 90% showed ISH signals. This means that 
when more than 90% of the cells within an aggregate contained one ISH sign­
al, it was classified as monosomy. Consequently, of it contained two or three 
ISH signals, it was classified as disomy and trisomy, respectively 
Results 
Development of the t e c h n i q u e 
The success rate of the ISH procedure using chromosome-specific DNA pro­
bes in interphase nuclei is mainly dictated by the accessibility of the target 
DNA. Therefore, the effect of different conditions, such as the fixative, pre-
treatment with agarase and proteolytic digestion, were studied. 
To avoid detachment of the agar preparations from the glass slides 
during pretreatment and ISH denaturation, the slides were coated with poly-
L-lysine. Fixation with 70% ethanol was sufficient to avoid loss of material 
from the slide and to preserve morphology during the permeabilization steps. 
To improve the accessibility of the target DNAs and to achieve good 
penetration of DNA probes and immunological reagents through the agar, a 
proteolytic digestion with pepsin or agarase was performed. Pretreatment 
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with pepsin, which removes a large part of the cytoplasmic and nuclear pro­
teins, was shown to be more effective than agarase in improving sensitivity 
and reproducibility. The most crucial parameter for the success rate of ISH, 
however, was a reduction of the agar layer thickness. We observed that a 
reduced volume of agar medium at a technical minimum of 0.8 5 ml instead of 
the standard 2.0 ml per dish resulted in about 90% analyzable nuclei. 
For the immunological detection assay, fluorochromes or peroxidase-
conjugated markers could be applied to detect the biotin-labeled probes The 
evaluation of ISH results by bright-field microscopy was preferred because of 
the permanency of the staining. Furthermore, fluorescent techniques are 
hampered by autofluorescence from the remaining agar. 
Exper imenta l results 
The ISH results of the bone marrow samples with the probes for chromoso­
mes 1 and 8 are summarized in Table 1 
Normal bone marrow cells from case 1 showed two ISH signals for 
both centromenc-associated probes (93% for chromosome 1 and 95% for 
chromosome 8) in the cells from the suspension preparation We also detec­
ted a low frequency of cells with one signal for these two probes (5 % and 4%). 
All the aggregates screened (n = 5 0) in the semisolid assay contained a majori­
ty of cells with two ISH signals (Fig. 1B). Within aggregates, about 10% of the 
nuclei showed one signal as a result of overlap of ISH signals. No differences 
in this respect were seen between chromosome 1 and chromosome 8. 
ISH on the interphase nuclei of the cells from the case 2 suspension 
preparation with a monosomy for chromosome 1, according to its karyotype, 
showed one ISH signal per nucleus in 71% and two ISH signals in 28%. 
Analysis of the semisolid assay showed that the majority of cells (about 80%) 
in the aggregates (n = 35) contained one ISH signal per nucleus for chromo­
some 1 (Fig. 1 A). A low percentage of cells (< 10%) was found with two ISH 
signals. The single cells in agar, however, showed 12% of the nuclei with two 
ISH signals and 88% with one ISH signal. Karyotyping revealed no chromoso­
mal aberration for chromosome 8. Hybridization of the cells from the suspen­
sion preparation and the semisolid assay with a chromsome 8-specific probe 
showed frequency distributions similar to the hybridization results for nor­
mal bone marrow cells. 
The nuclei of case 3 with a trisomy for chromosome 8 (46.XY/44, 
ΧΥ,-5 ,-6,+8,+marl ) showed three ISH signals in 94% of the nuclei in the cell 
suspension preparation. The majority of the nuclei in the aggregates (n = 64) 
contained three ISH signals (Fig. 1C), while the nuclei of the single cells in the 
agar demonstrated three ISH signals in 73% and two ISH signals in 12%. 
Furthermore, in this case 1 1 % of the single cells in the agar showed no signal 
at all. Even after repeated hybridizations, a low frequency of nonreacting cells 
was observed The results of hybridization with the chromosome-1 -specific 
probe were comparable to those of normal bone marrow cell. 
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T a b l e 1 Results from karyotyping and in situ hybridization procedures in single-cell suspension preparations 
and in the semisolid assay of bone marrow cells of a healthy donor and AML patients 
Cell suspension Semisolid assay 
Single cells in agar 
Case Diagnosis 
no 
Karyotype Probe for 0 
chromosome 
ISH signals/nucleus (%) ISH signals/nucleus (%) 
1 2 3 4 Aggregates« 0 1 2 3 4 
1 normal 
bone marrow 
AML 
AML 
AML 
46.XY 
46,ΧΥ/44,ΧΥ,-1,-5,·7, 
-17,+marl,+mar2, 
+2xmar3 
46,XY/44,XY,-5,-6 
+8,+mar1 
polyploid 
92-96 chromosomes 
XX 
1 5 93 1 0 disomy (n=50)° 2 4 94 0 0 
0 4 95 1 0 disomy (n=50) 3 3 92 2 0 
0 71 28 1 0 monosomy (n=35) 0 88 12 0 0 
0 9 91 0 0 disomy (n=23) 0 8 90 2 0 
0 6 94 0 0 disomy (n=50) 0 6 93 1 0 
0 1 5 94 0 trisomy (n=64) 11 4 12 73 0 
0 5 33 18 44 disomy (n=38) 0 2 32 16 50 
a For evaluation see Materials and methods. 
b Number of aggregates (clusters 5-40 cells; colonies >40 cells) analyzed. 
ISH on the interphase cells of case 4 with a polyploid karyotype (female, 92-
96 chromosomes) showed for chromosome 1 two (33%), three (18%) and 
four (44%) ISH signals in the single-cell suspension preparation. The single 
cells in agar also demonstrated the same distribution of ISH signal counts 
(Table 1 ), showing three and four ISH signals (Figs. 1 F, G). The main popula­
tion of cells within aggregates showed two ISH signals (Fig. IE). Within 
aggregates, however, a low percentage of cells with three or four ISH signals 
was observed (<20%). 
Discussion 
The approach described in this study demonstrates the application of the ISH 
technique for determining chromosomal aberrations in hematopoietic 
progenitor cells cultured in a semisolid assay. 
The distribution of the ISH signals in the interphase cells of the cell sus­
pension preparations was shown to be similar to those of the single cells in 
agar in all four cases. This means that these cells are representative of the total 
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Figure 1 Application of the in situ hybridization procedure to in vitro cultured progenitor cells from 
patients with AML 
a Almost all clonogenic cells of case 2 demonstrate one ISH signal per cell for chromosome 1,as 
detected by ISH on single cells and by karyotyping. 
b Part of an aggregate from normal bone marrow (case 1) showing two ISH signals per nucleus. 
с Three ISH signals per cell for the chromosome 8 centromeric-associated probe were detected in 
case 3, in which a trisomy 8 was karyotyped. 
d The cytological architecture of the agar assay remains intact. 
e, fand g. Case 4 was karyotyped as polyploid. The aggregates (e) demonstrated two ISH signals 
per nucleus, whereas single cells in the agar could be recognized showing three (g) or four (f) 
ISH signalsforchromosomel. 
cell population. In cases 2 and 4, a mixed cell population, according to the 
number of ISH signals for the probe for chromosome 1, was observed. The 
cells in the aggregates in each of these cases, however, revealed one type of 
ISH signal. In case 2, a monosomy and in case 4, a disomy could be detected, 
suggesting monoclonality of the progenitors. 
All the analyzed aggregates of cases 2 and 3 contained the clonal mar­
ker (monosomy 1 and trisomy 8, respectively), and no disomic aggregates 
were assessed. Therefore, they all confirmed the leukemic origin. In case 4, 
which had a polyploid karyotype, the aggregates were diploid. The aggrega­
tes demonstrated a mixed population, however-predominantly diploid cells 
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with a few polyploid cells (<20%). A possible explanation is that the large 
colonies overlapped the aneuploid cells in this case. This may be the result of 
the high plating concentration (8x10s cells per dish) that was required to 
obtain the colonies. 
The major advantage of the ISH approach over karyotyping is that not 
only metaphase spreads, but also interphase cells can be examined for chro-
mosomal aberrations. Therefore, at least 90% of the cells can be analyzed. 
Another advantage of the ISH approach is that the cytological architecture of 
the agar assay remains intact (Fig. 1D). This makes it possible to analyze small 
clusters containing about 5 to 20 cells; by previous techniques,4· ' 9 only large 
colonies coud be analyzed. Furthermore, the aggregates and single cells in 
agar can be analyzed individually. This makes it possible to discriminate 
between the clonogenic and non-clonogemc cells in a mixed population. The 
main advantage of ISH over the G6PD technique is that heterozygous females 
are not the only patients who can be monitored for the detection of progeni-
tor cells. 
ISH, using a specific chromosomal aberration as a marker, can now be 
applied in addition to cytogenetic analyses to determine the leukemic origin 
of in vitro cultured cells. Furthermore, the ISH technique enables the determi-
nation of the origin of blood and bone marrow progenitor cells in patients 
with myeloproliferative disorders at different stages of the patients' disease. 
Bone marrow can be maintained in culture for at least 10 days to serve as an 
autograft in patients with intensive chemo-radiotherapy It is assumed that 
normal stem cells survive this period better than leukemic stem cells.21 The 
ISH technique facilitates the detection of numerical chromosome aberrations 
in progenitor cells to monitor the in vitro culture system. 
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Summary 
Interphase cytogenetics was used to investigate the clonal origin of bone mar-
row (BM) cells, peripheral blood (PB) cells, and in vitro cultured progenitor 
cells of five patients with acute myeloid leukemia (AML) and myelodysplasia 
(MDS). A new in situ hybridization (ISH) technique was used to examine the 
origin of the progenitor cells. 
Two patients with, respectively, trisomy 8 and polyploidy as ISH mar-
ker were studied both at presentation and during remission At presentation, 
the in vitro cultured clusters of both cases appeared diploid. Therefore, despite 
the abnormal growth patterns, the cultured progenitors could have been resi-
dual normal cells. Alternatively, they could have originated from a preleuke-
mic clone with a normal karyotype. In both cases abnormal BM and/or PB cel-
ls (less than 6%) were detected with ISH during remission, indicating 
partially or completely clonal remissions in these patients. Both patients have 
relapsed. 
One patient with trisomy 10 as ISH marker was analyzed during mye-
lodysplasia phase and after progression to AML. On both occasions, abnor-
mally appearing clusters were cultured. However, only part of the clusters 
carried trisomy 10. The presence of a subclone characterized by trisomy 10 
and an abnormally growing (pre)leukemic clone without trisomy 10 may 
explain this observation. 
Monosomy 1 and 1 7 were respectively used as ISH markers in two 
other AML patients. All in vitro cultured clusters carried the numerical abnor-
mality. Long-term liquid cultures of these leukemias were performed for 10-
20 days. In both cases, no residual normal clonogenic cells could be detected. 
Therefore, the selective growth advantage of normal progenitor cells in long-
term marrow cultures could not be demonstrated in these two patients with 
leukemia. 
This paper illustrates the usefulness of ISH to study the biology of AML 
at the clonogenic level during preleukemic phase, active disease, remission, 
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and under in vitro culture conditions. It is a sensitive technique which allows 
individual analysis of large numbers of small aggregates and single cells in 
culture. 
Introduction 
Acute myeloid leukemia (AML) may be considered as a clonal expansion of 
one single transformed cell. ' ·2 The origin of the leukemic clone may be either 
a multipotential hematopoietic stem cell (HSC) or a cell restricted to the gra-
nulocyte-monocyte pathway.1 ·2 In myelodysplastic syndrome (MDS), the ab-
normal clone is assumed to arise at stem cell level.3 In the majority of 
AML/MDS cases, progenitor cells can be cultured in vitro.4"6 The origin of 
these clonogenic cells may be difficult to assess, since colonies derived from 
(pre) leukemic progenitors are not always morphologically distinguishable 
from those derived from normal progenitors.7 
Several techniques have been developed to determine the clonal origin 
of hematopoietic cells. In heterozygous females, the X-chromosome-linked 
enzyme glucose-6-phosphate dehydrogenase (G6PD) or restriction fragment 
length polymorphisms (RPLP) of other X-chromosomal enzymes can be used 
as a genetic marker.1·2,8 Karyotyping and surface marker expression analysis 
offer alternative approaches.2·9· ' ° Progenitors of AML patients at presentation 
are usually derived from the malignant clone. Occasionally, the myeloid colo-
nies appeared to originate from normal stem cells.7 During remission, in 
most patients restoration of nonclonal hematopoiesis and repopulation of the 
marrow by normal stem cells has been observed. Clonal remissions have also 
been observed.3·10·1 ' 
The results obtained with long-term bone marrow culture (LTBMC) 
of BM cells from AML patients additionally support the presence of residual 
normal stem cells in leukemic patients during active disease. In most cases, 
leukemic colonies and clusters were no longer detectable after 1 to 4 weeks of 
culture. '2" ' 4 The few reports about progenitors in MDS suggest the existence 
of a transformed stem cell either with or without an abnormal karyotype.5· ' 5 
Recently, we described a method to determine chromosomal aberra-
tions by ISH in myeloid progenitor cells cultured in agar. '6 · ' 7 The present stu-
dy investigates the genetic clonality of myeloid progenitor cells and nucleated 
cells in five patients with AML and MDS at different stages of their disease. 
Patients and Methods 
Patient selection
 P a t i e m s w i t h de novo A M L o r A M L after a myelodysplastic 
phase characterized by a numerical chromosomal aberration were selected for 
this study. AML and MDS were diagnosed according to the French-American-
British classification. '8 · ' 9 Patient 1 was assessed at diagnosis and in complete 
remission. He relapsed 6 months after the last analysis (May 1992). Patient 2 
presented with a leukemoid reaction during an exacerbation of her ulcerative 
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colitis. This was followed by a 'spontaneous' remission of 5 months without 
any antileukemic therapy. Patient 3 was investigated during the myelodys-
plastic phase and after leukemic transformation. Patients 4 and 5 were studied 
at presentation of AML. The relevant clinical and hematological data are 
shown in Table 1. 
T a b l e 1
 Clinical data 
Case Disease Age WBC Hb Platelets Blood BM FAB 
no Date status (yr) Sex (109/l| (mmol/l) (109/D % blasts % blasts type 
1 
2 
2/8B 
5/91 
11/91 
4/87 
9/87 
AML 
CR 
CR 
'leukemoid 
reaction' 
AML 
52 
3 
M 
F 
105 
86 
54 
43 6 
46 9 
64 
75 
69 
77 
74 
26 
173 
155 
236 
23 
3 
0 
1 
2 
42 
85 
0 
NA 
36 
80 
M4 
М4 
2/88 CR 67 78 140 
12/91 MDS 54 M 
5/92 AML 
73 
24 7 
71 
57 
30 
12 
2 6 
33 
RAEB 
M2 
5/89 AML 60 M 216 57 16 27 2B М б 
2/89 AML 58 M 8 6 5 6 29 73 75 М 2 
M, male, F, female, WBC, white blood cells; Hb, hemoglobin; BM, bone marrow, 
FAB, French-American-British classification™·™, NA, not available 
Cell collection, crvopreservation, and thawing
 D „,„„.., „„n„ „ . ι 
r K a
 Bone marrow cells were col­
lected, cryopreserved in liquid nitrogen and thawed as described in detail 
elsewhere.20 For ISH, cells were fixed in 70% ethanol (-20°C) and stored at 
-30°C until further use. 
Human recombinant growth factors Human recombinant interleukin 3 (IL-3) 
and human recombinant granulocyte-macrophage colony-stimulating factor 
(GM-CSF) were kindly donated by Sandoz BV (Uden, The Netherlands). 
Human recombinant granulocyte colony-stimulating factor (G-CSF) was a 
kind gift from Behring (Marburg, Germany). Final concentrations of 40 
ng/ml, 20 ng/ml, and 5 ng/ml respectively were used and resulted in plateau 
stimulation. 
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Clonogenic assay (CFU-C)
 C e U s w e r e c u l t u r e d l n I s c o v e ' s medium, supple­
mented with 20% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin (Flow 
Laboratories, Irvine, Scotland), and 0 3% (w/v) bacto-agar (Difco, Detroit, 
Michigan) The cells were stimulated with the combination of IL-3, GM-CSF, 
and G-CSF Duplicates were cultured in 35- χ 10-mm culture dishes (Costar, 
Cambridge, Massachusetts) at 37°C in a fully humidified atmosphere contai­
ning 5% CO2 In order to render the cells better accessible for the DNA probes, 
a reduced volume of 0 85 ml per dish was plated ' 6 After 7 days, the total 
number of clusters (5-40 cells) and colonies (>40 cells) was counted A pat­
tern of small (maximum size, 20 cells) or large (maximum size, 40 cells) clus­
ter formation was usually observed After counting, the agar cultures were 
dried by a method based on a technique described by Barnes 2 ' The cultures 
were shaken into glucose-phosphate buffer and divided into quarters Each 
quarter was spun down on a 76- χ 26-mm poly-L-lysine (Sigma, St Louis, 
Missouri, MW 150,000-300,000) coated glass slide by cytocentnfugation 
Samples were processed for ISH or stained with hematoxylin solution (Merck, 
Darmstadt, Germany) to evaluate morphology 
Liquid culture çe\\s were suspended in Iscove's medium supplemented with 
20% FCS, 50 IU/ml penicillin, 50 μg/ml streptomycin and a combination of 
IL-3, GM-CSF, and G-CSF The liquid cultures were maintained in an incuba­
tor (37°C, 5% CO2 and fully humidified atmosphere) for a period up to 20 
days At regular intervals, part of the cells were collected, washed, and used 
for clonogenic assay and ISH 
Karyotyping M
e t aphase S p r e ads were obtained from BM or PB cells after cul-
tunng in RPMI 1640 (Flow Laboratories) for 1 or 24 h Colcemid was present 
during the last hour of the culture Before fixation in methanol glacial acetic 
acid ( 3 1 ) , the cells were exposed to a hypotonic solution (0 07 5 M KCl) for 
15 min Slides were prepared according to routine cytogenetic procedures 
Karyotyping was performed using the GTG technique 
In situ hybridization
 K H w a s p e rf o r m e d o n c e l l suspensions and dried agar 
cultures as described before ' 6 For good penetration of the DNA probes and 
antibodies, a proteolytic digestion step with pepsin (P7000 Sigma) was per­
formed at a concentration of 100 μg/ml in 0 01 M HCl for 20 min at 37°C 
The nuclei were post-fixed in 4% formaldehyde in PBS for 20 mm at 4°C Ten 
microliters of the hybridization mixture (60% formamide, 0 6 M NaCl 60 
mM sodium citrate (2x SSC), 10% dextran sulphate, and a probe concentra­
tion of 1 ng/μΐ) was applied under a covershp Denaturation of target DNA 
and probe was carried out simultaneously at 70°C for 2 5 min in a moist 
chamber and hybridization was performed for 2-16 h at 3 7°C Subsequently, 
the hybridized probes were detected by horseradish peroxidase (HRP) conju­
gated avidin (Dakopatts, Glostrup, Denmark) Finally, the DNA probe was 
visualized with 0 5 mg/ml 3,3-diaminobenzidin tetrahydrochlonde (DAB, 
Sigma) ,0 65% imidazole (Merck) , 0 0 1 5 % H202 (Merck). at pH 7 8 in PBS 
As controls, the samples were hybridized with a chromosome-specific DNA 
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probe for which no chromosomal aberration was detected. In these controls, 
the cells from suspension preparations demonstrated one ISH signal for a tar-
get chromosome in 5-10% of the cells, and three ISH signals in <2% of the 
cells. Of these suspension preparations, 200 nuclei per slide were counted. 
The agar preparations were evaluated by counting 100 single cells and 
approximately 50 aggregates. In these controls, at least 90% of the cells con-
tained ISH signals. The percentages of cells containing the euploid number of 
ISH signals for the control DNA probe-targets varied between 85 and 
90%.16 '17 
Results 
Case 1 
Presentation of AML
 A t p r e s e n t a t l o n j ] 2 of 13 analysed BM cell metaphases 
showed trisomy 8 by karyotyping (Table 2). With ISH, trisomy 8 was found 
in 7 1 % of the BM cells. A leukemic growth pattern was observed with small 
clusters consisting of 5-25 immature myeloid cells After hybridization with 
the probe for chromosome 8, disomy was found in all analyzed clusters, 
whereas 14% of the single cells in the semi-solid culture had trisomy 8. 
Complete remission
 ¡ n
 Ш у ] 9 9 1 _ k a r y o t y p i n g r e v e a l e d only normal BM 
cells, whereas no metaphases could be detected in the PB. However, by ISH, 
6% of the BM cells showed trisomy 8. Both BM and PB exhibited a normal in 
vitro growth pattern. The colonies appeared morphologically normal and 
were diploid when analyzed with the probe for chromosome 8. By contrast, 
in the BM culture, respectively 19% and 4% of the single cells in agar had tri­
somy and tetrasomy for chromosome 8, whereas the single cells of the PB cul­
tures showed trisomy and tetrasomy 8 in respectively 12% and 2%. 
In November 1991 only PB was analyzed. No metaphases were detec­
ted. ISH on cell suspension was not performed. A normal growth pattern was 
observed demonstrating disomy 8 in all aggregates, while part of the single 
cells in culture had trisomy 8 (7%). 
Case 2 
At leukemic presentation, all investigated BM metaphases appeared to be 
polyploid, containing about 96 chromosomes (Table 2) For ISH analysis, we 
applied the probe for chromosome 1 in this particular case. 
'Leukemoid reaction'
 D u r i n g ' l e u k e m o i d Γ ε 3 α ί ο η ' , a normal karyotype was 
found in nine bone marrow metaphases (Table 2). In contrast, ISH revealed 
that 4% of the BM cells contained three or four ISH signals with the chromoso­
me 1 probe. The number of colonies in the semi-solid culture was depressed. 
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Morphology and size of the colonies appeared normal. All analyzed colonies 
were disomic, whereas 8% of the single cells in agar contained three or four 
ISH signals. 
Presentation r j
u r i n g overt leukemia, when all analyzed BM metaphases were 
polyploid, tri- or tetrasomy 1 was found by ISH in 62 % of the BM cells. Only 
very few colonies and clusters could be cultured in agar. They appeared to 
have normal morphology and size and were disomic when hybridized with 
the probe for chromosome 1. Sixty-six percent of the single cells in those cul­
tures were tri- or tetrasomic. 
Complete remission
 I n F e b r u a r y 1988, both normal and polyploid cells were 
detected by cytogenetic analysis ISH revealed tri- or tetrasomy 1 in 5% of the 
BM cells. Normal colony numbers were observed. Their morphology and 
size appeared also normal. All analyzed colonies were disomic, whereas 2% 
of the single cells in the semi-solid culture were tri- or tetrasomic. 
Case 3 
Karyotyping of the BM revealed that eight of 32 analyzed metaphases 
had trisomy 10 (Table 2). With ISH, 26% of the BM cells had trisomy 10.In 
the PB cells, on which no karyotyping was performed, 14% of the cells 
showed trisomy 10 by ISH. Both BM and PB cells were growing as clusters 
consisting of 5-35 immature cells. Although morphologically not distinguis­
hable, both clusters with and without trisomy 10 were observed by ISH in 
these cultures. The single cells in the BM and PB cultures demonstrated a triso­
my for chromosome 10 in 3 5% and 37%, respectively. 
Presentation д £ i e u ]ç e r m c presentation, no BM metaphases were detected. By 
ISH, 16% of the BM cells had trisomy 10. The clusters appeared morphologi-
cally identical to the clusters cultured during MDS phase. Trisomy 10 was 
found in seven of 30 clusters, whereas 8% of the single cells in culture showed 
trisomy 10. 
In the following two cases bone marrow was cultured in liquid in the pre-
sence of IL-3, GM-CSF, and G-CSF for up to 20 days to investigate whether 
residual normal progenitors had a growth advantage compared to the leuke-
mic clone. 
Case 4 
Presentation
 A ( ι
ε ι 1 ^ ε ι η ί ς presentation, karyotyping of BM cells revealed 
multiple abnormalities in almost all metaphases (Table 3). The probe for 
chromosome 1 was selected as a marker for ISH. Monosomy 1 was found in 
71 % of the BM cells. The in vitro growth pattern consisted of small clusters 
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Bone marrow and blood (case nos 1,2 and 3) 
Suspension Semi-solid 
Case Disease Cell Karyotype 
no Date status sample 
ISH (%) ISH ISH CFU-CC 
colonies/clusters single cells (%) colonies/clusters 
1 
2 
3 
2/88 
5/91 
5/91 
11/91 
4/87 
9/87 
2/88 
12/91 
5/92 
AML 
CR 
CR 
CR 
'leukemoid 
reaction' 
AML 
CR 
MDS 
AML 
BM 
BM 
PB 
PB 
BM 
BM 
BM 
BM 
PB 
BM 
46,XY/47,XY,+B 
|л = 1/12|а |92%] 
46,XY|n=32) 
no metaphases 
found 
no metaphases 
found 
46,ХХ(л=9) 
polyploid (about 96 
chromosomes, л=6) 
(100%) 
46,XX/polyploid 
(л = 14/2|(13%) 
46,XY/47,XY,+10 
(n =24/8) (25%) 
NA 
no metaphases 
found 
trisomy β (71) 
trisomy 8 (6) 
NA 
NA 
trisomy 1 |1) 
tetrasomy 1 (3) 
trisomy 1(18) 
tetrasomy 1 (44) 
trisomy 1 (2I 
tetrasomy 1 (3) 
trisomy 10 (26) 
trisomy 10(14) 
trisomy 10(16) 
disomy 8 (n = 17)b 
disomy 8 (n=21) 
disomy 8 (n = 18) 
disomy 8 (л = 18) 
disomy 1 (л = 17) 
disomy 1 (л =381 
disomy 1 |л=39) 
disomy 10 |n=6) 
trisomy 10 (n = 14) 
disomy 10 (л = 18) 
trisomy 10 (л = 17) 
disomy 10 (л=23| 
trisomy 10 (/7=7) 
trisomy 8 (14) 
trisomy 8 (19) 
tetrasomy β I4) 
trisomy 8 (12) 
tetrasomy В (2) 
trisomy 8 (7) 
trisomy 1 (21 
tetrasomy 1 (6) 
trisomy 1 (16I 
tetrasomy 1 (50) 
tnsomyl ( 1 | 
tetrasomy 1 (1) 
trisomylO (35) 
tnsomylO (37) 
trisomylO (8) 
0/89 
99/34 
33/20 
42/20 
12/21 
4/5 
140/14 
1/116 
1/43 
18/2160 
ISH, in situ hybridization; BM, bone marrow, PB, peripheral blood, CR, complete remission, NA, not analyzed 
в Number of mitosis. 
ft Number of analyzed aggregates. 
с Number of CFU-C per 2 χ IO5 NC (BM) or 8 χ 105 NC (PB) 
(5-20 cells) consisting of immature cells. All analyzed clusters and 88% of the 
single cells showed monosomy 1. 
iqui cu ture jjqU 1 (j culture for 10 days did not significantly influence the 
number of abnormal cells and clusters. Ninety-one percent of the cells in sus­
pension showed monosomy 1. Again only immature appearing small clus­
ters could be cultured, which all showed monosomy for chromosome 1. The 
single cells in the semi-solid assay demonstrated in 91 % a monosomy 1. 
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Bone marrow (cases 4 and 5) 
Suspension Semi-solid 
Case Days of liquid 
culture Karyotype ISH (%) 
ISH 
colonies/clusters 
ISH 
single cells (%) 
CFU-C' 
colonies/clusters 
presentation 46,XY/44,XY,-1,-5,-7, 
-17,-20,-21,+marl, 
+шаг2,+2ктагЗ 
(n=2/34|a|94%) 
day 10 
day 5 
day 10 
day 14 
day 20 
NA 
presentation 46,XY/43,X,3q,+8,+10, 
-5,-6,-12,-13,-17,-22,-Y 
+mar1-3(n = 1/9) 
(90%) 
NA 
NA 
NA 
NA 
monosomy 1 (71) monosomy 1 ( n = 3 5 ) b monosomy 11 0/380 
monosomy 1 (91) monosomy 1 (n=43) monosomy 1 (91) 0/180 
monosomy 17 (96) monosomy 17 In =42) monosomy 17 (82) 0/5400 
monosomy 17 (99) monosomy 17 (л=38) NA 0/5100 
monosomy 17 (96) monosomy 17 (л=55) NA 0/11000 
monosomy 17 (95) monosomy 17 (n=27) NA 0/4500 
monosomy 17(96) monosomy 17 (n=26) monosomy 17(841 0/900 
ISH, in situ hybridization, NA, not analyzed. 
a Number of mitosis 
b Number of analyzed aggregates 
с NumberofCFU-Cper2x105NC. 
C a s e 5 
Presentation j^ine
 o u t Qf JQ m e taphases showed multiple chromosomal 
aberrations (Table 3). In this case, monosomy 17 was chosen as ISH marker. 
Monosomy 17 was detected by ISH in 96% of the BM cells. The clusters con­
sisted of 5-25 immature cells and were all monosomic for chromosome 17. 
Moreover, monosomy 17 was found in 82% of the single cells in the semi­
solid assay. 
Liquid culture у ^
е
 j^g^ plating efficiency allowed in liquid culturing of the 
leukemic cells up to 20 days. Liquid culture cells and agar cultures (both 
single cells and clusters) were analyzed at regular intervals. During the whole 
period the proportion of abnormal cells in liquid remained essentially the 
same (95-99%). At any time, only aggregates with monosomy 17 were 
detected by ISH. 
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Discussion 
Five patients with de novo AML or AML after a myelodysplastic phase and ab-
normal clones characterized by numerical chromosomal abnormalities were 
subject of this study. In all cases, the chromosomal aberrations observed by 
cytogenetic analyses could also be detected by ISH. The percentage of abnor-
mal cells was within the same range for both methods taking into account the 
following considerations. Conventional cytogenetic analysis examines fewer 
cells than ISH and this may result in a less accurate estimation of the real num-
ber of abnormal cells. Furthermore, conventional cytogenetic analysis is per-
formed on dividing cells, which may lead to a selection for the abnormal sub-
population.9 Non-dividing interphase lymphocytes are included in the ISH 
analysis and cannot be analyzed by karyotyping. The lymphoid lineage is 
usually not a part of the abnormal clone and thus may account for the lower 
incidence of abnormal cells found with ISH.2 
The detection level of ISH analysis is more sensitive than conventional 
cytogenetic analysis, especially when trisomie or polyploic markers are used. 
The number of ISH signals is constant during the whole cell cycle, and in nor-
mal diploid cells the number of cells with four ISH signals is maximally 1 % 
(17). The sensivity level of three ISH signals is at the level of 2-4%. ISH analy-
sis detected 4% abnormal cells during the 'leukemoid' reaction of patient 2, 
while the 9 metaphases revealed 46 normal chromosomes. This result may be 
regarded as borderline significant, but the significance is further supported 
by the presence of 8% tnsomic or tetrasomic cells in the agar culture of this 
bone marrow. Remission marrow of patient 1 contained only normal meta-
phases and 6% abnormal interphase cells as measured with ISH. This patient 
had persisting abnormal cells in culture 6 months later and consequently 
relapsed. Similar observations have been made in G6PD and RFLP studies.7·22 
The ISH marker for abnormal cells was not detected in the cells of the 
clusters of patients 1 and 2. In both cases the bone marrow and blood cultures 
contained single cells with numerical abnormalities. The clusters could be the 
progeny of normal progenitor cells which exhibit an abnormal growth pat-
tern due to influences of adjacent leukemic cells. In the majority of reported 
cases, myeloid progenitors are part of the leukemic clone at presentation. 
However, in a few patients, normal CFU-GM have been detected.7 It is impor-
tant to realise that the ISH method enables the evaluation of small clusters and 
single cells in the cultures in situ while the methods based on G6PD isoenzy-
mes or genetic analysis require micromanipulation of the colonies. The latter 
analyses can only be performed on larger colonies and this may have influen-
ced the results. If the clusters in cases 1 and 2 did originate from normal cells, 
then the in vitro growth pattern and morphology by itself are not sufficient to 
determine the origin of progenitor cells. An alternative explanation could be 
that these progenitor cells represent a part of the leukemic clone without the 
numerical aberration. This concept can be explained by a multistep leukemo-
genesis with a preleukemic stage; an early step causes clonal proliferation and 
a later step results in a chromosomal abnormality in descendants of these 
progenitors.8·1 ' 
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In case 3 the progression from MDS to AML could be observed. The abnormal 
but identically appearing clusters could be distinguished in two subpopula-
tions. one consisting of progenitors with and the other without trisomy 10 
(Table 2). No increase in the percentages of either BM cells or progenitor cells 
with trisomy 10 was observed when the patient developed AML. Only the pla-
ting efficiency of cultured progenitors increased. This observation matches 
the theory that MDS arises from a transformed progenitor cell and progresses 
from a preleukemic state to overt leukemia by successive genetic changes.3- ' 5 
In that case, all cultured clusters belonged to a (pre)leukemic clone with 
abnormal growth characteristics, but only part of this clone obtained the 
chromosomal aberration trisomy 10. 
Patient 4 and 5 were selected because conventional cytogenetic analy-
sis revealed a subpopulation of normal metaphases (Table 3). All cultured 
clusters from these patients contained the numerical ISH abnormality. This 
was in agreement with the observed leukemic growth pattern and undifferen-
tiated appearance of the clusters, and confirmed the leukemic origin of these 
myeloid progenitors. Although in both cases part of the BM cell metaphase 
spreads and interphase nuclei appeared normal, no residual normal clonoge-
nic cells could be detected after long-term culture in liquid. In the majority of 
reported cases, long-term marrow cultures provide a selective growth advan-
tage for normal progenitor cells, but in some AML cases, as in patient 4 and S, 
persistence of the leukemia has been observed. '2" ' 4 
Forty to 70% of the AMLs and 25 to 50% of the MDSs have numerical 
chromosomal abnormalities, indicating that a substantial number of patients 
with AML and MDS can be analyzed by ISH using centromere associated DNA 
probes.23·24 Moreover, probes against fusion genes, such as bcr-abl gene, have 
become available.25 This may further increase the number of patients which 
can be studied by ISH techniques. By performing ISH on agar cultures, the 
cytological architecture remains intact. This enables individual analysis of 
large numbers of aggregates and single cells in the culture. Sample errors are 
avoided since removal of colonies is not necessary. In contrast to the conven-
tional techniques, not only large colonies but also small clusters can be analy-
zed. Furthermore, it is less time consuming to investigate large numbers of 
aggregates. Therefore, ISH may help to clarify the complex biology of MDS 
and AML both during 'full-blown' situation and clinical remission. In addi-
tion, it can be applied to monitor in vitro culture systems. Additional studies are 
needed to explain the nature of small aggregrates of some patients which have 
a normal diploid ISH signal. 
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Chapter 8 
Summary and conclusions 
Summary 
In both normal and leukemic hematopoiesis, stem cells generate large quanti­
ties of more or less differentiated end cells. Leukemic stem cells are held 
responsible for the maintenance of the leukemic clone. Therefore, the main 
target of antileukemic therapy is eradication of these leukemic progenitor 
cells with relative sparing of the normal bone marrow stem cells. 
Colony-forming assays are available to culture normal and leukemic 
clonogenic cells in vitro. In this thesis, clonogenic assays were used as models 
to study the Ara-C sensitivity, growth factor responsiveness, proliferation and 
clonal origin of leukemic progenitor cells. 
Chapter 1 introduces the normal and leukemic hematopoiesis, the in vitro 
growth of progenitors, the cell cycle, the activity of Ara-C, and interphase 
cytogenetics. Finally, an outline of the investigation is given. 
In Chapter 2 the cytotoxic effect of the cell cycle-specific agent Ara-C 
on clonogenic leukemic and normal bone marrow cells was investigated. To 
overcome kinetic resistance and to increase cytotoxicity, cells were exposed 
to Ara-C for extended time periods, that is, 5 and 10 days. Prolongation of the 
Ara-C exposure time from 5 to 10 days increased the toxicity towards the 
majority of the leukemic clonogenic cells but not towards normal CFU-GM. 
Significantly more leukemic clonogenic cells than normal CFU-GM were kil­
led after 10-day exposure to Ara-C ( I D 5 0 : 0.8 ± 0 . 6 χ Ι Ο 8 Μ, η = 9 and 5.7 ± 
2.8 χ ΙΟ"8 Μ, η = 4 respectively; ρ = 0.039). These results indicate a preferen­
tial kill of leukemic versus normal clonogenic cells by prolonged Ara-C expos­
ure. 
In Chapter 3 the stimulation of leukemic clonogenic cells by individual 
growth factors was related to Ara-C sensitivity. Blasts of AML patients were 
exposed to IL-3, GM-CSF, G-CSF, and combinations of these hematopoietic 
factors. Heterogeneity in response was observed resulting in a variable 
growth factor pattern for individual leukemias. Compared to the toxicity in 
the absence of growth factors, exposure to Ara-C for 10 days in the presence 
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of optimal stimulatory factors resulted in a 3- to 1000-fold increase of the 
Ara-C toxicity in seven patients. The ID50 concentrations were 0.48 - 123 χ 
ΙΟ"
8
 M Ara-C in the absence of growth factors, versus only 0.12 - 0.40 χ 
Ι Ο
8
 M Ara-C in the presence of stimulatory factors. In two patients, neither 
stimulation of the leukemic progenitor cells nor enhancement of the Ara-C 
toxicity was observed after addition of one or more factors. These results 
indicate that Ara-C cytotoxicity can be enhanced by individually selected, clo-
nogenic cell growth promoting hematopoietic factors. 
In vitro suicide techniques are assumed to reflect the proportion of 
colony-forming cells in S-phase at the time of exposure, but they are not 
always accurate. In Chapter 4, a new IdUrd application was developed to inves­
tigate the proliferation of hematopoietic progenitor cells. IdUrd is incorpora­
ted into DNA during S-phase and can be visualized by immunoperoxidase 
containing antibodies. Colony-forming cells in S-phase during the IdUrd 
exposure were postulated to give rise to IdUrd"1" colonies. Toxicity, sensitivi­
ty, and IdUrd inactivation studies indicated that progenitor cells could safely 
be pulse-labeled for 2 hours with 40 μΜ IdUrd, whereas prolonged labeling 
with 1 μΜ was at least feasible for 5 days. The IdUrd pulse-labeling was com­
pared with the golden standard, 3H-TdR suicide. Wide confidence intervals of 
the suicide technique contrasted the small confidence intervals obtained with 
IdUrd pulse-labeling. In our hands, the IdUrd pulse-labeling was more accu­
rate than the 3H-TdR suicide technique. 
The prolonged IdUrd labeling technique was used in Chapter 5 to inves­
tigate whether growth factors influence the kinetics of leukemic clonogenic 
cells and thus alter the sensitivity to the cell cycle-specific drug Ara-C. Results 
were compared with the effects on normal CFU-GM. Liquid cultures were 
performed in the absence and presence of preselected combinations of IL-3, 
GM-CSF and G-CSF The median percentages of cycling CFU-L, measured by a 
3-day IdUrd labeling period, increased significantly (p = 0.009) from 8.5% 
without growth factors to 8 7.5% with growth factors in five tested non-spon-
taneously growing leukemias. The Ara-C sensitivity increased median 63-
fold (range 14-217). Ara-C appeared to be preferentially cytotoxic to CFU-L 
going through S-phase. Two spontaneously growing leukemias demonstra­
ted a high proportion of CFU-L in S-phase (93% and 99.3%) and were highly 
Ara-C sensitive regardless whether exposed to the combination of IL-3, GM-
CSF, and G-CSF or not. Different leukemias with a comparable proportion of 
cycling CFU-L were not equally Ara-C sensitive, suggesting other than cell 
cycle-specific mechanisms of toxicity. The three tested normal bone marrows 
showed a more uniform response pattern. Even in the absence of growth fac­
tors, 70%-80% of CFU-GM were cycling. This increased to 100% in the pre­
sence of the combination of IL-3, GM-CSF, and G-CSF and resulted in median 
4.3-fold (range 1.4-5.3) enhancement of Ara-C toxicity. Our data indicate 
that the increment of cycling leukemic clonogenic cells by growth factors 
may help to overcome the kinetic resistance to Ara-C in AML patients. 
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Leukemic blast samples may contain residual normal progenitor cells. 
Morphology alone can not always discriminate between leukemic and nor-
mal aggregates. Therefore, additional techniques like karyotyping, immuno-
phenotyping, and G6PD analysis (X-linked polymorphism) have been deve-
loped to establish the leukemic origin of progenitor cells. These techniques 
have their intrinsic limitations. In Chapter 6 a novel in situ hybridization (ISH) 
technique was developed to determine the presence of chromosomal aberra-
tions in progenitors in agar cultures. This technique retains the cytological 
architecture, allowing evaluation of large and small colonies and non-clo-
nogenic cells in culture Not only metaphase cells, but also interphase cells 
could be evaluated. 
In Chapter 7 this new ISH technique was applied to investigate the clonal 
origin of bone marrow (BM) cells, peripheral blood (PB) cells, and in vitro 
cultured progenitor cells of five patients with AML and MDS with an abnor-
mal chomosomal pattern. Patients were studied during preleukemic phase, 
active disease, and remission. All (pre)leukemic samples demonstrated 
abnormal growth at presentation (hypoplastic or small clusters). In two cases 
the ISH marker was not present in the aggregates, suggesting residual normal 
progenitors or a leukemic subclone with a karyotype without the ISH marker. 
In two cases a low percentage (maximally 6%) of abnormal BM and/or PB 
cells was detected with ISH during remission. Consequently, these remissions 
could have been partially or completely clonal. In one case, typed as M6, the 
percentage of BM cells with the ISH marker was much higher (71 %) than the 
amount of blasts (28%) This indicated that at least part of the normoblasts 
belonged to the abnormal clone, suggesting a multipotent stem cell origin. 
Long-term liquid cultures of two leukemias were performed for 10-20 days. 
In both cases, no residual normal clonogenic cells could be detected. 
Therefore, the reported selective growth advantage of normal progenitor 
cells in long-term marrow cultures can not be demonstrated in all patients 
with leukemia. 
Conclusions 
• Prolonged exposure to Ara-C may overcome kinetic resistance of slowly 
proliferating leukemic stem cells. 
• Induction of leukemic stem cells into proliferation with individually selec-
ted appropriate hematopoietic growth factors may overcome kinetic re-
sistance. 
• The new technique utilizing IdUrd to measure proliferation is a more accu-
rate technique to assess proliferation in clonogenic cells. 
• The development of a new ISH technique allows detection of numerical 
chromosomal aberrations in clonogenic cells. This technique facilitates 
research on leukemic stem cells. 
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Samenvatting 
Normale en leukemische hematopoietische stamcellen zorgen voor de pro-
duktie van min of meer gedifferentieerde eindcellen. De leukemische stam-
cellen zijn verantwoordelijk voor het voortbestaan van de leukemische kloon. 
Het belangrijkste doel van antileukemische therapie is het uitroeien van deze 
leukemische stamcellen en tegelijk het behoud van voldoende normale been-
mergstamcellen. 
Normale en leukemische progenitorcellen kunnen in vitro gekweekt 
worden middels donogene assays Deze assays zijn in dit proefschrift 
gebruikt als modellen om de Ara-C gevoeligheid, de groeifactor gevoelig-
heid, de proliferatie en de clonale origine van leukemische progenitorcellen 
te bestuderen. 
Hoofdstuk 1 geeft uitleg over de normale en leukemische hematopoiese, de in 
vitro groei van progenitorcellen, de celcyclus, de werking van Ara-C en inter-
fase cytogenetica. Tot slot wordt een overzicht van het onderzoeksplan ge-
geven. 
Het cytotoxische effect van het S-fase specifieke middel Ara-C op leu-
kemische en normale donogene cellen wordt bestudeerd in Hoofdstuk 2. Om 
kinetische resistentie te kunnen overwinnen werden de cellen langdurig aan 
Ara-C blootgesteld, d.w.z. gedurende 5 en 10 dagen. Verlenging van de Ara-C 
expositieduur van S naar 10 dagen verhoogde de toxiciteit t.a.v de meerder-
heid van de leukemieën, maar met t.o.v. de normale CFU-GM. Significant 
meer leukemische donogene cellen dan normale CFU-GM werden gedood 
tijdens de 10 dagen blootstelling aan Ara-C (ID5 Q ' 0 8 ± 0.6 χ 1 0 8 Μ, η = 9 en 
5 7 ± 2.8 χ 10"8M,n = 4 respectievelijk; ρ = 0.039). Deze resultaten suggere­
ren dat leukemische donogene cellen gevoeliger zijn voor langdurige bloot­
stelling aan Ara-C dan normale donogene cellen. 
De relatie tussen Ara-C toxiciteit en groeifactor gevoeligheid werd 
onderzocht in Hoofdstuk 3. Blasten van AML patiënten werden gestimuleerd 
met IL-3, GM-CSF, G-CSF en combinaties van deze 3 factoren. Elke leukemie 
bleek zijn eigen individuele gevoehgheidspatroon te hebben. Tien dagen Ara-
C blootstelling in aanwezigheid van optimaal stimulerende factoren deed de 
Ara-C toxiciteit 3 tot 1000 maal toenemen in 7 patiënten in vergelijking met 
de toxiciteit in afwezigheid van groeifactoren. De ID50 Ara-C concentraties 
waren 0.48 - 1 23 χ 10"8 M in de afwezigheid van groeifactoren versus 0.12-
0.40 χ 10"8 M in de aanwezigheid van stimulerende groeifactoren. In 2 
patiënten konden de leukemische progenitorcellen niet gestimuleerd worden 
door groeifactoren. De Ara-C gevoeligheid nam in deze gevallen met toe na 
toevoeging van groeifactoren. Bovenstaande resultaten wijzen erop dat Ara-C 
toxiciteit verhoogd kan worden door individueel geselecteerde, donogene 
celgroei bevorderende groeifactoren. 
Van 111 vitro suicide technieken wordt verondersteld dat ze het percenta-
ge donogene cellen in S-fase ten tijde van de expositie weergeven. Deze testen 
blijken niet altijd even accuraat. Een nieuwe IdUrd toepassing om de proli-
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feratie van hematopoietische progenitors vast te stellen wordt beschreven in 
Hoofdstuk 4. IdUrd wordt ingebouwd in DNA gedurende de S-fase en kan zicht­
baar worden gemaakt door aan specifieke antilichamen gekoppeld peroxida­
se. Uit donogene cellen, die in S-fase waren gedurende de IdUrd blootstel­
ling, ontstaan IdUrd"1" colonies. Bestudering van toxiciteit, sensitiviteit en 
IdUrd inaktivatie toonde aan dat progemtorcellen konden worden gelabeld 
gedurende een korte incubatie van 2 uur met 40 μΜ IdUrd, terwijl langdurige 
labeling met 1 μΜ IdUrd gedurende tenminste 5 dagen mogelijk was. De 
IdUrd puls labeling werd vergeleken met de gouden standaard, de thymidine 
suicide techniek De betrouwbaarheidsintervallen van de IdUrd labeling 
waren kleiner dan die van de suicide techniek. De IdUrd puls labeling was in 
onze handen nauwkeuriger dan de suicide techniek. 
In Hoofdstuk 5 werd langdurige IdUrd labeling toegepast om te onder­
zoeken of groeifactoren de kinetiek van leukemische donogene cellen veran­
deren en daarmee ook de gevoeligheid voor het S-fase specifieke cytostaticum 
Ara-C. De resultaten werden vergeleken met de effekten op normale CFU-
GM. Cellen werden gekweekt in de aan- en afwezigheid van geselecteerde 
combinaties van IL-3, GM-CSF en G-CSF. Bij S niet spontaan groeiende leuke-
mieën was na 3 dagen IdUrd labeling het mediane percentage CFU-L in S-fase 
8.5% in de afwezigheid van groeifactoren en 87.5% in de aanwezigheid van 
groeifactoren (p = 0.009). De Ara-C gevoeligheid nam mediaan 63 maal toe 
(spreiding 14-217) wanneer groeifactoren aanwezig waren. Ara-C was bij 
voorkeur toxisch voor CFU-L in S-fase. Twee spontaan groeiende leukemieën 
vertoonden een hoog percentage CFU-L in S-fase (93% en 99.3%) en waren 
zeer gevoelig voor Ara-C zowel in aan- als afwezigheid van de combinatie van 
IL-3, GM-CSF en G-CSF. Verschillende leukemieën met een vergelijkbaar per-
centage CFU-L in S-fase waren niet even gevoelig voor Ara-C. Dit suggereert 
dat ook andere dan celcyclus specifieke mechanismen van Ara-C toxiciteit een 
rol kunnen spelen. Het beenmerg van 3 normale donoren vertoonde een 
meer uniforme reaktie. Zonder exogene groeifactoren waren 70% tot 80% 
van de CFU-GM in S-fase. In de aanwezigheid van de combinatie van IL-3, 
GM-CSF en G-CSF nam dit toe tot 100% en nam de Ara-C toxiciteit mediaan 
4.3 maal toe (spreiding 1.4-5.3). De resultaten geven aan dat de door groei-
factoren veroorzaakte toename van leukemische donogene cellen in S-fase de 
kinetische resistentie voor Ara-C kan doen verminderen in AML patiënten 
Leukemisch beenmerg kan naast blasten ook residuale normale proge-
mtorcellen bevatten. Morfologisch kunnen leukemische aggregaten niet 
altijd goed onderscheiden worden van normale aggregaten. Om die reden 
zijn aanvullende technieken ontwikkeld zoals karyotypering, immuno-feno-
typering en G6PD analyse (X-linked polymorfisme). Bovengenoemde tech-
nieken hebben hun beperkingen. In Hoofdstuk 6 wordt een nieuwe in situ 
hybridisatie (ISH) techniek beschreven waardoor chromosomale afwijkin-
gen in progenitors in agarbodems vastgesteld kunnen worden. De cytologi-
sche architectuur blijft onbeschadigd waardoor zowel grote als kleine colo-
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mes en niet donogene losse cellen beoordeeld kunnen worden. Niet alleen 
metafase cellen, maar alle interfase cellen kunnen worden bestudeerd. 
Deze nieuwe ISH techniek werd toegepast in Hoofdstuk 7 om de clonale 
origine vast te stellen van beenmergcellen, perifere bloedcellen en in vitro 
gekweekte progenitorcellen van 5 patiënten met AML of MDS met een afwij-
kend chromosomenpatroon. De patiënten werden bestudeerd tijdens preleu-
kemische fase, aktieve ziekte en remissie. Alle (pre)leukemieën vertoonden 
een abnormaal groeipatroon (hypoplastisch of kleine clusters). De aggrega-
ten van 2 patiënten bevatten de ISH marker niet. Dit suggereert de aanwezig-
heid van residuale normale progenitors of een leukemische subkloon met een 
karyotype zonder de ISH marker. Een klein percentage (maximaal 6%) abnor-
male beenmerg en/of bloedcellen kon worden aangetoond in 2 leukemieën 
m remissie. Deze remissies zijn blijkbaar geheel of gedeeltelijk klonaal 
geweest. Het beenmerg van een type M6 leukemie bevatte meer cellen met de 
ISH marker (71%) dan het aantal blasten (28%). Dit wijst erop dat ten minste 
een deel van de normoblasten tot de abnormale kloon behoorden, hetgeen 
past bij een multipotente stamcel origine. Cellen van 2 patiënten met leuke-
mie werden gedurende 10 tot 20 dagen doorgekweekt. In beide kweken kon-
den geen residuale normale donogene cellen worden aangetoond. Het gerap-
porteerde groeivoordeel van normale progenitors in lange termijn kweken 
kan kennelijk niet gedemonstreerd worden in elke leukemie. 
Conclusies 
• Langdurige blootstelling aan Ara-C kan de kinetische resistentie van lang-
zaam prolifererende leukemisch stamcellen verminderen. 
• Proliferatie-induktie van leukemische stamcellen met individueel aange-
paste hematopoietische groeifactoren kan de kinetische resistentie reduce-
ren. 
• De nieuwe Idurd techniek maakt een meer accurate vaststelling van de pro-
liferatie van donogene cellen mogelijk. 
• Door de ontwikkeling van een nieuwe ISH toepassing zijn numerieke 
chromosomale afwijkingen te constateren in donogene cellen. Dit vereen-
voudigt leukemisch stamcel onderzoek. 
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